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INTRODUCTION 
  
The role of thyroid gland in pregnancy and the impact of thyroid 
disorders in pregnancy and fetal development has drawn a tremendous interest 
in the recent years. Thyroid disorders are the second most common 
endocrinological disorders in pregnancy. There is a wide geographical 
variation in the prevalence of hypothyroidism in pregnancy. It varies from 
2.5% in western countries to 11% in India. The incidence is therefore higher in 
Asian countries compared to the West. 
               In view of the adverse outcomes associated with maternal thyroid 
disorders and the obvious benefits of treatment, some expert panels have 
suggested routine thyroid screening. However the endocrine society clinical 
practice guideline recommend a case finding approach where only women at 
risk are tested. These include those with a personal or family history of thyroid 
disorders, type 1 diabetes mellitus, or any other history suggestive  
Autoimmune disorders, goitre, thyroid antibodies, History of head or neck 
irradiation, or history of preterm delivery, Infertility, history of recurrent 
abortion. 
                In a recent study by Dhanwal et al, a high prevalence of 
hypothyroidism was noted. (14.3%) Looking at these data, the purpose of my 
study was to find out whether routine screening will be beneficial in our 
country compared to the high risk screening strategy.  
                                                                                  
 
                 Evidence suggests that sub clinical hypothyroidism may be 
associated with spontaneous abortion, preeclampsia, abruption, preterm 
delivery, and impaired cognitive and psychomotor development in the 
offspring.  
                 The yield and cost effectiveness of screening are dependent not only 
on the range of screened population, but also on the variables used and cut-off. 
So cut-off has to be adjusted according to trimester specific values.  
                  Maternal hypothyroidism in the first trimester may be harmful to 
the fetal brain development. These complication can be prevented if universal 
screening is done and adequate treatment is started in first trimester as 
treatment after that will not reverse the established neurodevelopment delay. 
As in the first trimester, the fetus entirely depends on maternal thyroid 
hormones for neurodevelopment. 
          The causes for hypothyroidism include iodine deficiency, 
autoimmune thyroiditis, radioactive iodine therapy or surgical removal of 
thyroid gland. 
                  The incidence of hyperthyroidism in pregnancy is less than 1%. 
Moreover sub clinical hyperthyroidism does not affect pregnancy outcome. So 
the screening mainly focuses on hypothyroidism.  
           
                                                                                  
HISTORY 
 
Goitres (Latin- guttur), defined as enlargement of the thyroid gland have 
been recognised since 2700 BC. The term thyroid gland (Greek- thyreoeides, 
shield shaped) was however coined by Thomas Wharton in 1656.It was 
thought to have various functions ranging from acting as a reservoir of blood 
to provide continuous supply to brain to beautifying women’s neck. Seaweed 
was considered as a treatment for goitre. In 1909, Kocher was awarded Nobel 
Prize for his work on the pathology, and surgery of the thyroid gland. William 
Gull, Governor of Guy’s Hospital, in 1874 was the first to describe 
myxoedema and what he called a “cretinous state in the adult”. In 1883, Dr. 
Dawtrey Drewitt presented a patient with the classical symptoms of 
hypothyroidism in the Clinical Society of London The earliest oral treatment 
for hypothyroidism consisted of thyroid extract. The first treatment of 
hypothyroidism with thyroid extract in 1891, was described by George 
Redmayne Murray in UK. The first recorded American use was as early as 
1891 by a woman who was taking it till 84 years of age. 
                                                                                  
 
EMBRYOLOGY 
 
Around the third week of gestation the thyroid gland arises as a 
primitive out pouching of the primitive foregut. It originates at the base of 
tongue near the foramen caecum. Endodermal cells in the pharyngeal anlage 
thicken to form the medial thyroid anlage. This descends in the neck anterior 
to the hyoid bone. During this descent, the thyroid anlage remains connected to 
the foramen caecum by the thyroglossal duct. The thyroid follicular cells arise 
from the epithelial cells of the thyroid anlage. The fourth brachial pouch gives 
rise to the paired lateral analogues which fuse with the medial thyroid anlage. 
The lateral analogues are neuroectodermal in origin and secrete calcitonin. 
Colloid formation begins in the thyroid follicles by the eleventh week of 
gestation.. 
                                                                                  
 
 
                                                                                  
ANATOMY OF THROID GLAND 
 
                                                                                  
The adult thyroid gland is brown in colour and firm in consistency and 
is located posterior to the strap muscles. The normal thyroid gland weighs 
approximately 20 g, but gland weight varies with body weight and iodine 
intake. 
            The thyroid lobes are located adjacent to the thyroid cartilage and 
connected in the midline by an isthmus that is located just inferior to the 
cricoid cartilage. A pyramidal lobe is present in about 50% of patients. The 
thyroid lobes extend to the midthyroid cartilage superiorly and lie adjacent to 
the carotid sheaths and sternocleidomastoid muscles laterally. The strap 
muscles (sternohyoid, sternothyroid, and superior belly of the omohyoid) are 
located anteriorly and are innervated by the Ansa cervicalis (Ansa hypoglossi). 
The thyroid gland is enveloped by a loosely connecting fascia that is formed 
from the partition of the deep cervical fascia into anterior and posterior 
divisions. The true capsule of the thyroid is a thin, densely adherent fibrous 
layer that sends out septa that invaginate into the gland, forming 
pseudolobules. The thyroid capsule is condensed into the posterior suspensory 
or Berry’s ligament near the cricoid cartilage and upper tracheal rings 
 
BLOOD SUPPLY 
The superior thyroid arteries arise from the ipsilateral external carotid 
arteries and divide into anterior and posterior branches  
 
                                                                                  
NERVE SUPPLY  
The left RLN arises from the vagus nerve where it crosses the aortic 
arch, loops around the ligamentum arteriosum, and ascends medially in the 
neck within the tracheoesophageal groove. The right RLN arises from the 
vagus at its crossing with the right subclavian artery  
 
 
                                                                                  
 
HISTOLOGY  
 
Microscopically, the thyroid is divided into lobules that contain 20 to 40 
follicles. There are about 3 × 106 follicles in the adult thyroid gland. The 
follicles are spherical and on an average 30 μm in diameter. Each follicle is 
lined by cuboidal epithelial cells and contains a central store of colloid 
secreted from the epithelial cells under the influence of the pituitary hormone 
TSH. The second group of thyroid secretory cells is the C cells or 
parafollicular cells, which contain and secrete the hormone calcitonin. They 
are found as individual cells or clumped in small groups in the interfollicular 
stroma and located in the upper poles of the thyroid lobes  
                                                                                  
 
 
 
                                                                                  
 
THYROID PHYSIOLOGY  
Iodine metabolism and increased Iodine requirement in pregnancy: The 
average daily iodine requirement is 0.1mg. Fish, milk, eggs and iodised salt are 
rich sources of iodine. In the stomach and jejunum iodine is rapidly converted 
to iodide and absorbed into the blood stream. Iodide actively enters the thyroid 
follicular cells by an ATP dependent process. Thyroid stores nearly 90% of 
body’s iodine. The excess plasma iodine is excreted through the kidneys. The 
WHO recommends a daily intake of 250mcg of iodine for pregnant and 
lactating women because the increase in thyroid hormone production in 
pregnancy requires an equal increase in iodine availability.D3(placental 
deiodinase ) removes iodine from T3 & T4,generating inactive iodothyronines 
and reverse T3.This also prevents large amounts of T4 from crossing the 
placenta. Another reason for increase in iodine demand is increased GFR with 
an increased urinary clearance of iodine. Although the fetal thyroid starts 
developing by 12 wks of gestation, it cannot organify iodine till 20wks of 
gestation. Till that period the maternal T4 is the only form of the hormone that 
can cross the placenta. Deiodinase enzyme in the fetus converts maternal fT4 
to T3 in brain & other tissues. So the fetal iodine store solely demands on 
maternal intake during this period. 
 
                                                                                  
Thyroid hormone synthesis, secretion and transport: 
The first step in the synthesis of thyroid hormone is iodide trapping. It is 
an ATP dependent active transport across the basement membrane of the 
thyroid follicular cells. The thyroid follicles contain thyroglobulin (TG) which 
is a glycoprotein with four tyrosyl residues. The second step in the synthesis of 
thyroid hormones involves iodide oxidation to iodine followed by iodination of 
tyrosyl residues on the thyroglobulin. Both processes in this step are catalysed 
by thyroid peroxidase. The end products of the second step are mono and 
diiodotyrosine (MIT&DIT). The third step involves their coupling to form 
tetra iodothyronine (T4) or one monoiodotyrosine and one diiodotyrosine 
molecule to form triiodothyronine (T3) or reverse triiodothyronine (rT3). 
Hydrolysis of the thyroglobulin molecule to release free iodothyronines 
(T3and T4) and mono and diiodotyrosines is the fourth step. The later are 
deiodinated in the fifth step yielding iodide which is reused by the thyrocyte. 
                                                                                  
Thyroid hormones are transported in serum bound to thyroxine binding 
globulin (TBG), thyroxine binding prealbumin (TPBA) and albumin. Only a 
small fraction of thyroid hormone is free and this is the physiologically active 
hormone. T3 is three to four times more potent than T4. The circulating levels 
of T3 are much lower when compared to T4 and is less tightly bound to 
proteins. Hence it enters tissues more easily. T3 has a half-life of one day 
while T4 has a half-life of seven days. In euthyroid state T4 is released entirely 
by the thyroid gland while only 20% of T3 is released by thyroid. The 
remaining 80% of T3 is produced by deionization of T4 in liver, kidneys and 
muscles.  
 
                                                                                  
Metabolism and excretion of thyroid hormone: 
Metabolic inactivation of T3 occurs by glucuronide conjugation and de 
iodination. Liver is the primary site although salivary glands and kidneys also 
play a role. The conjugates are excreted in bile. A major fraction is 
deconjugated in the intestines and re absorbed by entero hepatic circulation to 
be finally excreted in urine. 
 
 
Mechanism of action: 
T3 penetrates cells and combines with a nuclear receptor. Certain 
specific DNA sequences have been identified in regulatory regions of specific 
genes. The T3 receptor complex binds to these specific DNA sequences 
leading to depression or in some cases direct activation of gene transcription 
resulting in expression of predetermined pattern of protein synthesis. Many of 
the clinical manifestations of thyroid hormone like tachycardia, hypertension, 
arrhythmias, tremor, and hyperglycaemia are mediated partly if not completely 
by sensitisation of adrenergic receptors to catecholamines. 
 
Thyroid hormones enter the cells by diffusion and binding of thyroid 
hormones to the nuclear receptors of cells results in translation and 
                                                                                  
transcription of hormone specific genes. They affect almost every system in 
the body. They play an important role in fetal brain and skeletal development. 
Growth and development: Its role in growth and development can be 
understood by its action on the metamorphosis of tadpole to frog. Its action 
cannot be labelled catabolic or anabolic. It exerts a critical control over protein 
synthesis. Deficiency of thyroid hormone mainly affects the nervous system in 
early life. In cretinism there is retardation and nervous deficit as a result of 
paucity of synapse formation axonal and dendritic ramification and reduced 
myelination. In adult overt hypothyroidism also there is impairment of 
intelligence and movements are slow. 
Intermediary metabolism: Thyroid hormones have an important role in 
carbohydrate, lipid and protein metabolism. 
Carbohydrate: They stimulate carbohydrate metabolism. Although utilisation 
of carbohydrates is increased due to an increase in BMR, gluconeogenesis and 
glycogenolysis compensate for it. So hyperglycaemia and a diabetic like state 
occur in hyper thyroidism. 
 
Protein: The overall effect of T4 is catabolic. Negative nitrogen balance and 
tissue wasting result from prolonged action. This explains the weight loss in 
hyperthyroidism and weight gain in hypothyroidism. Thyroid hormones inhibit 
mucoprotein synthesis in low concentrations which characteristically 
accumulates in myxoedema. 
                                                                                  
Lipid: T4 and T3 indirectly enhance lipolysis although lipogenesis is also 
stimulated. Cholesterol metabolism is accelerated but its conversion to bile 
acids dominate. Thus hypocholesterolaemia is a feature of hyperthyroidism 
and hypercholesterolemia and obesity are features of hypothyroidism. 
Calorigenesis: Basal metabolic rate is increased by stimulation of cellular 
metabolism and resetting of the energystat. But the metabolic rate in uterus, 
gonads, brain, spleen and lymph nodes is not significantly affected. The 
mechanism is uncoupling of oxidative phosphorylation thus releasing excess 
energy as heat. 
Cardio vascular system: 
Heart rate, contractility and output are increased which cause a fast and 
bounding pulse. Thyroid hormones act on the contractile elements of the heart 
and stimulate them by upregulation of beta adrenergic receptors. They have a 
positive Inotropic and chronotropic effect. Actions of catecholamines are 
augmented. That is why fibrillation and arrhythmias are common in 
hyperthyroidism. It can also precipitate angina. Blood pressure particularly 
systolic is often raised. Myocardial oxygen consumption can be markedly 
reduced by induction of hypothyroidism. 
Nervous system: They maintain the normal hypoxic and hypercapnic drive in 
the respiratory centre of brain .Mental retardation is the hallmark of cretinism. 
Sluggishness and other behavioural features are seen in myxoedema whereas 
tremors, anxiety and hyperreflexia are seen in hyperthyroidism. 
                                                                                  
Skeletal muscle: Thyroid hormones increase the protein turnover and speed of 
muscle contraction and relaxation .Myxoedema is characterised by flabby and 
weak muscles while thyrotoxicosis causes an increase in muscle tone, tremor 
and weakness due to myopathy. 
Gastro intestinal system: Thyroid hormones increase gastric motility. 
Hypothyroid patients are often constipated while diarrhoea occurs in 
hyperthyroidism. 
Kidneys: 
They have no effect in euthyroid individuals but cause diuresis when 
myxedematous patients are treated with them.Haematopoesis: Anaemia occurs 
in hypothyroid individuals, thus it is proven that T4 plays a role in 
erythropoiesis. 
Reproduction: Oligomenorrhoea and subfertility/infertility is known to occur 
in women with hypothyroidism. Normal functioning of the thyroid gland is 
essential for maintenance of pregnancy and lactation 
 
 
               
 
 
 
                                                                                  
THYROID PHYSIOLOGY IN PREGNANCY 
Pregnancy is associated with changes in thyroid physiology in the 
mother. Thyroid hormone is derived from iodination of tyrosine residues in 
thyroglobulin to form mono or di iodo tyrosine which are then coupled to form 
T4 and T3. The majority of T4 that is released is bound to circulating transport 
proteins thyroxine binding pre albumin and albumin, thyroxine binding 
globulin (TBG). The free fraction represents 0.04% of total T4 and is the 
physiologically active hormone or free T4. Anterior pituitary secretes TSH 
which increases the synthesis and release of thyroid hormone. During 
pregnancy there is an increase in estrogen mediated production of TBG.The 
increased binding of thyroid hormone together with its increased Metabolism 
by the placenta leads to a greater requirement for thyroid hormone production 
in order to maintain free T4 levels. Total T4 levels are above the normal non 
pregnant levels. There is also an increase in renal clearance of thyroid 
hormone in pregnancy. All these along with increase in placental transfer of 
iodine to the fetus in turn results in increased maternal demand for iodine 
which is necessary for thyroid hormone production. Women who have 
borderline iodine deficiency may be unable to meet this increased demand 
resulting in reduction in thyroid hormone production.HCG belongs to a family 
of glycoprotein hormones which also includes TSH with a common alpha 
subunit and unique beta subunit. However there is considerable homology 
between beta subunits of human chorionic gonadotropin and TSH. So HCG 
                                                                                  
has weak TSH like activity. Serum thyrotropin (TSH) level in early pregnancy 
is reduced because of  the thyroid stimulating effect from the weak TSH 
effects of HCG. So there is also a slight increase in free T4 levels. There are 
pregnancy conditions associated with higher than usual HCG levels such as a 
molar gestation, hyperemesis gravidarum or multiple gestation. These may 
result in an exaggerated stimulation of the thyroid gland and transient first-
trimester thyrotoxicosis. TSH will rebound to normal nonpregnant levels once 
HCG returns to a steady state. So there will be a mild decline in free T4 and an 
increase in TSH after the first trimester. But these changes typically remain 
within the reference range. That is why FT4 and TSH levels should be 
interpreted after comparison with specific reference ranges for each trimester. 
 
 
 
 
                                                                                  
                                                                                  
 
 
                                                                                  
 Cut off values for TSH in pregnancy: 
In normal pregnancy, because of the suppressive effect of increasing 
thyroxin and increased TSH excretion, TSH is kept at its lowest minimal level 
or can even go below normal range. In populations defined as euthyroids in 
various studies, TSH level is always 0.1-1.6 mIU/ml and thyroxin level is 
increased one and half times in pregnancy. In a study by Spencer et al in 2005, 
S.TSH >2.5 mIU/ml in 1st trimester showed T4 insufficiency (7).In a study 
conducted by Green WL in the year 2005, true and normal range of TSH is 
defined as in the range of 0.5- 2.5mIU/ml (6) Sufficient replacement therapy 
must be given when the TSH is above the level of 3mIU/ml and/or with a low 
T4, or the FT4 in pregnancy. Prof. Ladenson has rightly said, this should be 
considered as Gestational hypothyroidism. 
Thyroid physiology in the fetus and neonate: 
The human fetus starts to concentrate iodine and to synthesise hormone 
between 8 and 10 weeks of gestation along with the synthesis of TSH from the 
pituitary. Even though the pituitary thyroid axis is completely developed at 12 
to 14 weeks of gestation its function is minimal until a sudden surge in the 
fetal TSH occurs at 20 weeks. The fetal TSH levels continue to increase till 28 
weeks after which it reaches a plateau and remains at the same level till term. 
Free T4 
Concentration increases progressively till term and exceed maternal 
levels. Hence some level of fetal hyperthyroidism exists at term. Weeks of 
                                                                                  
pregnancyT4 is the major fetal thyroid hormone and the level of T3 is quite 
low throughout the gestation. However the levels of RT3 are elevated 
paralleling the rise of T4. During delivery the fetus goes from a state of 
relative T3 deficiency to T3 thyrotoxicosis. Shortly after birth the TSH values 
rise rapidly and later falls to the baseline values by 48-72 hours. In response 
the T4 and T3 levels increase and reach the peak values by 24-48 hours and 24 
hours of age respectively. The thyroidal hyperactivity takes about 3-4 weeks to 
completely disappear.  
These thyroid changes are believed to be a protective mechanism 
against sudden entry of the foetus into the cold environment. The high RT3 
levels during gestation return to the baseline at 2 weeks after reaching peak 
levels during the first 72 hrs of life.  The above changes occur mainly due to 
TRH surge as a response to rapid neonatal cooling since the TSH surge is 
accompanied by a prolactin surge. These thyroid changes are believed to be a 
protective mechanism against sudden entry of the foetus into the cold 
environment. The high RT3 levels during gestation return to the baseline at 2 
weeks after reaching peak levels during the first 72 hrs of life. 
 
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
Summary of fetal and neonatal thyroid changes  
 
TSH and T4 start appearing at 10-13 wks. of gestation.  Levels reach an abrupt 
rise at 20 wks.  T4 rapidly rises and exceeds maternal values at term  T3 values 
rise, but levels are relatively low, similar to hypothyroid adults  RT3 values 
exceed normal adult values  The fetal pattern of low T3 and high RT3 is 
similar to the levels seen in calorie deprivation  After birth, TSH peaks at 
30mins, followed by a T3 peak at 24 hrs and T4 peak at 24hrs.  High RT3 
values persist for 3-5 days after birth, then plateau down to normal values by 2 
wks. 
 
 
                                                                                  
Maternal Hypothyroidism: Causes of Hypothyroidism- 
Autoimmune 
Iodine deficiency (most common)   
Hashimoto thyroiditis 
De Quervian's thyroiditis 
Iatrogenic cause  
Thyroidectomy                                     
Previous radio-iodine   treatment                               
Drug therapy (eg.lithium, amiodarone)                                                
Congenital hypothyroidism                                             
Thyroid agenesis           
Thyroid dyshormonogenesis  
Infiltrative disorders Overt Hypothyroidism: This is characterised by an 
elevated TSH and low Thyroxine levels. The incidence of overt 
hypothyroidism in pregnancy is 0.3-0.5 %( 12) the adverse effects include 
miscarriages, anaemia, pre-eclampsia, abruption, PPH, premature birth, LBW, 
Increased neonatal respiratory distress. (12)In a study conducted by Jones WS 
et al in the American Journal of Obstetrics and Gynaecology in the year of 
1969 a conclusion had been made that preterm deliveries are more frequent in 
pregnant women with low thyroxine levels. 
 
                                                                                  
In a study by Leung AS et al in 1993 it was found that overt hypothyroidism 
resulted in an increase in incidence of gestational hypertension, preeclampsia 
and low birth weight babies. (14)In a study Allan WC et al in 2000 it was 
concluded that fetal demises were significantly increased in patients with TSH 
greater than 10mIU/ml.Davis et al in the year 1988 followed 25 hypothyroid 
women through 28 pregnancies who were divided into two groups, of which 
16 were clinically hypothyroid and 12 had subclinical hypothyroidism. This 
study had showed that pregnant  mothers with overt hypothyroidism were  at 
the risk for pregnancy induced hypertension , preterm delivery, placental 
abruption, stillbirth, postpartum haemorrhage and cardiac-dysfunctionACOG 
practice bulletin on thyroid disease in pregnancy(2001) states that untreated 
hypothyroid patients are at a increased risk of pre-eclampsia and inadequate 
treatment is also associated with low birth weight infants.(26)In an Indian 
study by Sahu MT et al published in Archives of gynaecology and obstetrics in 
2010, it was noted that IUGR ,gestational hypertension and IUD were 
increased in women with overt hypothyroidism. 
 
A couple of studies have shown low thyroxine concentration in early 
pregnancy can be associated with low intelligent quotient of children at 7 years 
of age.Ohara N et al in  the year 2004 had conducted a review of the literature 
on the role of thyroid hormone in  functions of trophoblast cells and  
neurodevelopment of fetus .  They had  concluded that close scrutiny of 
                                                                                  
maternal thyroid hormones was needed  to ensure sufficient  hormone levels in 
early pregnancy are of significant importance in prevention of abortions  and 
neurological deficits in infants(15)A study  which had been conducted by 
Evelyn Man and his colleagues in 1969 had compared the outcomes of 1252 
normothyroxinemic pregnancies with 168 hypothyroxinemic pregnancies.30 
out of the 168 hypothyroid women had ended up having fetal death or preterm 
deliveries(19.6%) compared to only12.6 % in the euthyroid category .Only 
few reports were available on the pregnancy outcome in hypothyroid pregnant 
women who did not receive any treatment strategy . These available data 
shows us that adequate and sufficient thyroxine hormone replacement 
improves complications but it does not totally suppress the frequency of 
significant obstetric complications. (8) 
 
 
 
 
 
 
 
 
 
 
                                                                                  
CLASSIFICATION OF THYROID DISORDERS 
 
FREE T3 FREE T4 TSH DIAGNOSIS 
NORMAL NORMAL NORMAL EUTHYROID 
ELEVATED ELEVATED LOW HYPERTHYROID 
LOW LOW ELEVATED HYPOTHYROD 
NORMAL NORMAL ELEVATED SUBCLINICAL 
HYPOTHYRODISM 
NORMAL NORMAL LOW SUBCLINICAL 
HYPERTHYROISDISM 
 
 
 
 
 
 
 
                                                                                  
SUBCLICAL HYPOTHYROIDISM 
By definition, it is a condition in which there is TSH elevation, but 
Normal free T4.. Incidence of subclinical hypothyroidism is at  2.5%  .It is 
usually asymptomatic, Subclinical hypothyroidism was more common in 
women who delivered  before 32 completed weeks.(12)Patients who had 
subclinical hypothyroidism had a 3 to 4 times increased risk of having 
placental abruption and 2 to 3 times  increased risk of preterm delivery 
compared to  women with normal Thyroid status .(22)Pre-eclampsia also was  
more commonly seen  in these patients .(23)Even raised maternal TSH  was  
associated with respiratory distress in new-born , pregnancy losses and preterm 
labour (12).The patients who were diagnosed as hypothyroidsm during 
antenatal period  continue to be hypothyroid even after pregnancy but it  
depends on the initial TSH value at diagnosis .The United States Preventive 
Services Task force  had reported that  almost nearly  all patients who had an 
initial TSH >10 mIU/ml had developed overt hypothyroidism within few years 
( mostly  5 years) .(33) 
Isolated Hypothyroxinaemia: It is defined as a condition with normal TSH but 
low free T4.  Goldman and his colleagues in the year 2008 had screened 
10,990 patients for presence of thyroid dysfunction .They found that isolated 
hypothyroxinemia in first trimester was associated with an increased incidence  
of preterm deliveries  and  large for gestation macrosomic  babies and if it 
                                                                                  
occurred in 2ndtrimester , it was associated with GDM and impaired glucose 
tolerance.  
 
CLINICAL FEATURES OF HYPOTHYROIDISM  
Hypothyroidism which develops in infancy resulted in 
neurodevelopmental delay and may even cause rectal prolapse, hernia in 
umbilical region and abdominal distension. Mental performance is decreased 
to some extent but severe retardation is not seen usually. In adults symptoms 
are usually nonspecific like fatigue, weight gain, cold intolerance, constipation 
and menstrual disturbances like menorrhagia or oligomenorrhoea, irregular or 
heavy flow. Patients with myxoedema have coarse facial features, Skin is 
yellowish due to reduced conversion of carotene to vitamin A. Hair is  brittle 
and there is also a characteristic loss of the outer two third of eye brow. 
Untreated patients may develop dementia or memory loss which is known as 
myxoedema madness. There is reduced libido and impaired fertility in both 
males and females.  Cardio vascular changes usually include bradycardia, 
pericardial and pulmonary effusions. 
 
 
 
 
                                                                                  
Treatment of hypothyroidism  
 Levothyroxine  
          Levothyroxine or T4, is a synthetic form of the thyroid hormone, which 
is normally secreted by the thyroid follicular cells. Levothyroxine is 
chemically in the chiral L-form. Edward Calvin Kendall of the Mayo clinic 
first isolated thyroxine in its pure form from extracts of hog thyroid glands .In 
1914 The hormone Was first synthesised by British chemist Charles Robert 
Harington in 1927.Absorption of L thyroxine is incomplete varying from 50-
70%. For most therapeutic purposes L thyroxine is superior to lio thyronine 
because of its longer duration of action. The only accepted indication for the 
use of lio thyronine is myxoedema coma where a quick response is essential. 
Levothyroxine should be taken on an empty stomach approximately half an 
hour before meals. Patients should avoid taking calcium and iron supplements 
within 4 hours of taking thyroxine as these can interfere with the absorption of 
this drug. According to the American Thyroid Association, pregnant women 
already being treated with thyroxine hormone often require a 30-50% increase 
in dose. The need for the increase in dose starts as early as 5 weeks of 
gestation. The association urges physicians to be vigilant in identifying and 
treating women with subclinical thyroid dysfunction before conception. The 
Journal of Clinical Endocrinology and Metabolism published an Executive 
Summary which stated that, in patients who had overt hypothyroidism the dose 
                                                                                  
of thyroxine should be adjusted to reach a TSH value of not more than 2.8 
IU/ml. The Thyroxine dosage has to be increased by 4-6 wks. of gestational 
age and requires a increase of 30-50%. If a patient at any time during 
pregnancy is diagnosed to have overt hypothyroidism, dose is titrated rapidly 
to keep the TSH not more than  2.5 IU/ml in the first trimester and less than 3 
IU/ml in second trimester and third trimesters. The panel had recommended 
thyroxine replacement in women with symptomatic or a symptomatic 
subclinical hypothyroidism. 
Hypothyroidism complications in pregnancy include Spontaneous 
miscarriage, Pregnancy induced hypertension (pre-eclampsia, eclampsia)   
abruption  IUGR  Oligohydramnios, Preterm delivery, Fetal distress, Low birth 
weight. 
 
 
 
 
 
 
 
 
 
                                                                                  
Thyroid dysfunction and pregnancy loss 
Normal thyroid function is an important part in maintaining normal 
reproductive functions. Gonadal steroid synthesis by the ovaries depends on an 
adequate thyroid hormones. T3 maintains the regulating action of FSH and LH 
on steroid hormone biosynthesis. The thyroid hormones usually increase and 
enhance estrogenic responses (9).Abnormal thyroid function is associated with 
anovulatory and irregular cycles, subfertility. Miscarriage rate were as high as 
60% in insufficiently treated overt hypothyroids and 70% in subclinical 
hypothyroids(10)Matsua et al had showed that Free T3 and Free T4 values 
were s much  lower in women who had recurrent abortions .(40)Donmez M et 
al in  the year 2005  had did a case control study to find out if  thyroid 
dysfunction  was an causative factor for abortions. They had performed thyroid 
function tests in 60 patients who had spontaneous abortions and compared 
them with those of 40 pregnant women of same gestational age who were at 
term gestation. They found that T3 and T4 values were lower and TSH values 
were higher among the recurrent abortion group. 
 
 
 
 
 
 
                                                                                  
Causes   of HYPERTHYROISDISM  
Intrinsic thyroid disease 
Graves’ disease 
Toxic nodule  
Subacute thyroiditis  
Exogenous thyroid hormone  
Gestational thyrotoxicosis  
Hydatiform mole 
 
HYPERTHYROIDISM IN PREGNANCY  
Subclinical hyperthyroidism does not affect pregnancy outcome and 
treatment not needed. Graves’ disease is in fact the most common cause of 
hyperthyroidism in pregnancy. Gestational transient thyrotoxicosis is due to 
cross reactivity between HCG and TSH at receptor .spontaneous resolution by 
18 weeks. 
 
EFFECTS OF HYPERTHYROISDISM  
On pregnancy  
 Spontaneous abortion  
 Preterm birth 
 Pre-eclampsia  
                                                                                  
 Abruption 
 IUGR  
 Congestive heart failure  
 Thyroid storm  
 Perinatal morbidity and mortality    
On fetus  
 Congenital malformation of heart, kidney or brain  
 Fetal Graves’ disease  
 Low birth weight  
 High output cardiac failure  
 Fetal goitre 
 Craniosyntoses  
 
Principles of management  
 Treatment and adequate metabolic control is associated with improved 
pregnancy outcome  
Propyl thiouracil drug of first choice because it partially inhibit conversion of 
T4 to T3 and crosses placenta less readily than methimazole  
Methimazole use in early pregnancy has been associated with oesophageal and 
choneal atresia and aplasia cutis in fetus.  
 
                                                                                  
DEFINITION OF SCREENING  
   Screening is the systematic and active search of a health problem by 
applying a test on a large scale in apparently healthy people. The idea is that 
early detection and treatment are beneficial. Screening tests aren’t intended to 
be diagnostic. Screening must be cost effective to beneficial. 
 
SCREENING FOR THYROID DYSFUNCTION IN PREGNANCY  
For universal screening to be recommended for a disease, the incidence 
of the disease should be high enough to warrant screening.  The screening 
needs to be as cost effective as possible there should be substantiative evidence 
that adverse outcomes are associated with the disease.  There should also be 
evidence that intervention improves outcomes. The journal of clinical 
endocrinology and metabolism had recommended a guideline in 2007 which 
stated screening among the following high risk women (27) 
a)Women who had  previous history of hyper /hypo thyroid disease / 
thyroidectomy /goitre) Women with family history of thyroid dysfunction) 
Women with symptoms/signs suggestive of thyroid dysfunction) Women with 
autoimmune diseases like Type 1 diabetes ) Women with a history of 
infertility) Women with history of head and neck irradiation) Women with 
history of recurrent abortion or preterm deliveries .According to the ACOG 
Committee Opinion no.381(oct 2007) also thyroid screening in pregnancy 
                                                                                  
should be carried out only on symptomatic women / those with a history of 
thyroid disease or other medical illnesses that may be associated with thyroid 
disease (eg:diabetes  
In a study by Bijay Vaidya et al published in JCEM in 2007,they found 
that thyroid function testing of only high risk women would miss about 1/3 
with overt/subclinical hypothyroidism.(21) 
 
IMPORTANCE OF UNIVERSAL SCREENING 
 
Thyroid  dysfunction is the second most common endocrine dysfunction 
in women of reproductive age next to diabetes .About 2-3% are diagnosed 
with hypothyroidism and 0.1 -0.4% with hyperthyroidism. Some studies have 
shown association with subclinical hypothyroidism and adverse maternal and 
fetal outcome. 
            The possible adverse outcomes of thyroid disorders in pregnancy are 
causing an increase in tendency for universal screening. However the AaCE, 
ACOG ATA do not recommend universal thyroid screening and recommend 
TARGETTED high risk case finding. 
          Many studies which compared various screening approaches reported 
that by not using an universal thyroid screening strategy resulted in 
overlooking a significant number of pregnant patients with thyroid 
                                                                                  
dysfunction. It has been shown that 30-90% of women with thyroid 
disturbance may be omitted using TARGETTED high risk approach. 
       In this study we aim to compare the universal screening with 
TARGETTED high risk case finding approach for early diagnosis of thyroid 
disorders in pregnant Indian women from district of Theni, tamilnadu, India  
 
 
 
 
 
                                                                                  
 
 
 
AIM OF THE STUDY 
 
 To substantiate the need for universal thyroid screening in pregnancy. 
 
 To find the incidence of undiagnosed thyroid disorders which would be 
missed by case finding approach  
 
 To study the outcome of patients with thyroid disorders both with 
adequate and inadequate treatment. 
                                                                                  
REVIEW OF LITERATURE 
 
Vaidya et al. (1) from the UK had stated that about thirty % of women 
who had hypothyroidism and 69% of women who had hyperthyroidism are 
being overlooked using the targeted high-risk case finding approach which is 
used routinely. 
   A study by Wang et al showed that a case identification screening 
strategy had failed to diagnose 81.6% of pregnant women with hypothyroidism 
and 80.4% of pregnant women with hyperthyroidism which is a significant 
population. 
In a retrospective cohort study, Chang et al. (2) from China also 
reported that 80% of women with high TSH levels could not be diagnosed 
using the high-risk case finding approach. 
  The Yang et al.  Study (5) showed that using the high-risk case finding 
strategy, all the women with overt hypothyroidism and 66.7% of women with 
overt hyperthyroidism were identified in the first trimester, indicating that this 
method is inefficient for identification of patients with overt thyroid disorders.  
The Ohashi et al.  Study (3) had also showed that targeted high-risk case 
finding approach for the diagnosis of thyroid disorders in pregnant women 
identified only 10% of women with thyroid dysfunction, i.e. 90% of women 
with thyroid dysfunction were not identified and were missed out. 
                                                                                  
  Ahmed et al.  Also reported that the case finding approach introduced 
by The Endocrine Association, 34.5% of pregnant women with clinical or 
subclinical hypothyroidism were being missed. . Yang et al.  Had used cut-off 
values of 3.47 mU/l in the first trimester and 3.81 mU/l in the second trimester 
for TSH. 
  Various prevalence of assumed risk factors for thyroid disorders (e.g. 
age and BMI) in different populations could explain these variations in results 
partly. 
The Dave et al study in Madhya Pradesh had showed the incidence of 
thyroid dysfunction in high risk population was 20.58% and in normal 
population it was 6.7%. So screening only the high risk population will miss 
out this 6.7 percent, which approximates to one third of the population. 
 
       
 
                              
 
 
 
 
 
                                                                                  
MATERIALS AND METHODS 
  The study was   carried out in 400 pregnant patients with singleton 
gestation at the antenatal clinic at government Theni medical college, Theni, 
from October 2016 to September 2018 during the first antenatal visit. All 
patients gave informed consent to participate in the study. At the same time 
patients with known hypothyroidism/ hyperthyroidism were excluded from the 
study.  
TYPE OF STUDY  
Prospective study 
DURATION OF STUDY  
October 2016 to September 2018 (24months) 
STUDY GROUP  
 400 pregnant women having their first trimester Antenatal booking visit at 
GTMCH AN OP. 
INCLUSION CRITERIA  
All pregnant women having their first trimester booking visit at 
GTMCH and who are willing to come for follow up. 
High risk group include patients with known autoimmune disorders, 
personal/ family history of thyroid disorders, obesity, recurrent Abortion, 
history of IUD, long period of infertility.  
 
                                                                                  
EXCLUSION CRITERIA  
Patients with known thyroid disorders  
Patients not willing to come for follow up  
Patients with molar pregnancy  
 
METHODS  
           On the enrolment of participants, an informed written  consent was 
taken , detailed history was enquired from patients and attenders, participants 
were subjected to relevant general physical examination, and findings were 
recorded on a pre-designed Proforma.  
  TSH and free T4 was measured in their first booking visit. Early 
morning fasting venous sample was being used. Patients were universally 
screened for thyroid dysfunction and values are noted down and analysed 
grouping patients into normal / overt hypothyroidsm/ overt hyperthyroidism, 
subclinical hypothyroidism/ subclinical hyperthyroidism and treatment was 
initiated. Patients are then analysed for risk factors for thyroid dysfunction, 
and if present, they are grouped into high risk group and those without risk 
factors into low risk group. Proportion of thyroid dysfunction in both groups 
are noted and was analysed if screening only high risk population rather than 
universal screening is sufficient.  
                                                                                  
Information was collected about abortion, abruption, preterm, low birth 
weight, fetal neonatal death and mode of delivery and birth weight. 
Complications in the sufficiently treated and inadequately treated group was 
noted down.   
The statistical difference between the variables were compared by chi 
square test (p value) 
Testing procedure 
3 ml blood sample was collected from the participants under strict 
aseptic precaution and blood samples were analysed in the same laboratory. 
Estimation of FT3, FT4, and TSH was done. 
                   The normal range of TSH was taken as 0.5 to 2.5 in first 
trimesters. The subjects underwent a detailed assessment of hypothyroidism 
risk factors as defined by the guidelines. 
                 Women with FT3, FT4 below the reference ranges long with 
elevated TSH>2.5 were diagnosed as overt hypothyroidism. Women with FT3, 
FT4 in normal range with TSH > 2.5 were diagnosed as having sub clinical 
hypothyroidism. Women with FT3, FT4above the reference range with 
TSH<0.1 was classified as overt hyperthyroidism .while those having FT4 FT3 
in normal range with TSH less than 0.1were diagnosed as subclinical 
hyperthyroidism. These women with abnormal thyroid profile will be started 
on treatment and followed up till term and watched for any complications. 
  
                                                                                  
 
ESTIMATION OF TSH 
 Specimen collection  
        Blood was collected in dry tubes or tubes containing EDTA in a fasting 
state. Serum/plasma were separated from cells by centrifugation. These 
samples were then stored at 2 to 8 degree Celsius. 
Method  
     Solid phase two stats immunoradiometric assay (IRMA) with IRMAK 9 kit. 
Principle  
In IRMA, two antibodies generated against different portion of the same 
antigen are used. One of the antibodies of the test   is bound to a solid phase, 
while the other antibody is labelled with iodine 125. Thus the antigen binds 
both the antibodies in a fashion which was similar to a sandwich. The 
radioactivity in the bound fraction was quantitated using a gamma camera. 
Reagents  
 hTSH ,monoclonal antibody coated tubes  
 Iodine 125 anti hTSH 
 Wash diluents  
 Control  
Serum or plasma can be used for assay .EDTA plasma is not used. 
    
 
                                                                                  
 
Results  
Normal range of TSH was taken as 0.1 to 2.5 micro units / ml. (in first 
trimester)  
ESTIMATION OF FREE T4 
 Method  
   Radio immuno assay  
Principle  
The radioimmunoassay if FT4 is a competitive assay which was done by using 
labelled antibodies. Samples and calibrator was incubated with an 
 I 125 labelled antibody specific for T3 as tracer in tubes was coated with an 
analogue of T4 ligand. The ft4 and ligand compete for binding to the 
labelled antibody. The content in the tube is aspirated after incubation 
and bound radioactivity is measured. A calibration curve was designed 
and values were ascertained by interpretation from the curve. 
REAGENTS  
 Ligand coated tubes 
 I 125 labelled monoclonal antibody  
 Control serum  
 Calibrators  
 
 
                                                                                  
RESULTS  
Normal range of free T4 was taken as 11.5 to 23 picomole/ litre  
ESTIMATION OF FREE T3  
    Principle, reagents and procedure are similar to free T4 estimation. 
 RESULTS  
Normal range of free T3 was taken as 2.5 to 5.8 picomole/ litre  
 
STATISTICAL ANALYSIS 
Demographic variables in categories were given in frequencies with their 
percentages. 
 Age was given in mean and standard deviation. 
Difference between thyroid profile and clinical variables are analyzed using 
chi square test 
Association between TSH and T3, T4 were analysed using McNemar’s test. 
Prevalence of Thyroid Dysfunction was calculated using percentage with 95% 
confidence interval 
Simple bar diagram, Multiple bar diagram,   Pie diagram, Doughnut diagram , 
and subdivided   bar diagram were used to represent the data . 
P<0.05 was considered statistically significant. All statistical test are two tailed 
test. 
 
                                                                                  
 
CHI-SQUARE TEST 
The Chi square test is a non-parametric test of proportions. It is used to 
test a hypothesis. If the association between two variables is to be tested this 
test is commonly used. It was introduced by Karl Pearson. 
The chi-square test is designed to examine whether a series of observed 
numbers in various categories of the data are consistent with the numbers 
expected in these categories on some specific hypothesis. (Called null 
hypothesis) 
The quantity of 
2 
describes the magnitude of discrepancy between 
2
test, we are in a position to know 
whether a given discrepancy between theory and observation may be attributed 
to chance or not. 
The qua
2   
is defined as: 
2   
=     (O-E )2  / E 
 (Observed frequency- expected frequency)2/ Expected frequencies 
Where O= observed frequencies 
            E = expected frequencies   
2   
=     {( O-E) - 0.5}2  /  E 
 
 
 
                                                                                  
Conditions of Chi-square test 
1. There must be large number of observations (say >50) 
2. All the observations must be independent  
3. Values/categories on independent and dependent variables must be mutually  
    Exclusive and exhaustive. 
4. The sample must be randomly drawn from the population.  
5. Calculations must be based on actual numbers of observations and not on 
     Percentages, ratios, observed values etc.) 
6. When overall total is between 20 and 40, all expected values are at least 5    
 
Arithmetic Mean 
   x
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Standard Deviation: A measure of the dispersion among the elements in a set 
of data. 
Standard deviation can be defined as follows:  
   
 
 
                                                                                  
OBSERVATION 
 
Table 1: THYROID PROFILE 
 
Thyroid status No. of women % 
 Normal 340 85.0% 
Abnormal 60 15.0% 
 Total 400 100.0 
 
                                                                 
   Fig 1 
 
                                                                                  
 
 
 
 
 
 
 
 
                                                                           
                                                         
   FIG 2 
 
 
 
Table 2 : TYPES OF THYROD DYSFUNCTION 
Types No. of women % 
 Subclinical hypothyroidism 34 56.7% 
Subclinical hyperthyroidism 6 10.0% 
Overt hypothyroidism 16 26.7% 
Overt hyperthyroidism 4 6.6% 
Total 60 100.0 
                                                                                  
 
                                                        
                                                    
  
            
      
                                                         
                                                                  
THYROID RISK FACTORS
0
0.00%
0
0.00%
  
The chi square value was 247.334. P value < 0.001, which is statistically 
significant. Which means a significant no of patients will be missed out if 
we use the targeted high risk screening.  
Table 3: THYROID RISK STATUS 
Risk  status No. of women % 
 With Risk factors 38 63.3% 
Without Risk factors 22 36.7% 
 Total 60 100.0 
                                                                                  
 
 
                                                                         
 
 
 
 
 
Risk factor No. With abnormal 
thyroid profile 
Percent 
Recurrent abortion. 
 
7 18.4% 
Family history 6 15.78% 
Hilly area 5 13.15% 
Obesity 5 13.15% 
Symptoms 6 15.78% 
Autoimmune 5 13.15% 
Advanced age 4 10.52% 
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Table 4 : LEVEL OF TSH 
Types No. of women % 
 <0.10 ng/ml 10 2.5% 
0.1 - 3.0 ng/ml 340 85.0% 
3 - 5 ng/ml 16 4.0% 
> 5 ng/ml 34 8.5% 
Total 400 100.0 
 
                                                                                  
Table 5: COMPLICATIONS 
 
Complication No. of women % 
 Yes 60 15.0% 
No 340 85.0% 
 Total 400 100.0 
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TABLE 6 
 Thyroid status Chi square test 
Abnormal 
thyroid profile 
Normal 
thyroid profile 
n % n % 
Missed Abortion 2 8.3% 0 0.0% 2=16.47 
P=0.05*(S) PIH 4 16.7% 6 16.7% 
IUGR 4 16.7% 0 0.0% 
Oligohydramnios 6 25.0% 9 25.0% 
Preterm 4 16.7% 11 30.6% 
Abruption 2 8.3% 2 5.6% 
IUD 2 8.3% 2 5.6% 
GDM 0 0.0% 4 11.1% 
Polyhydramnios 0 0.0% 2 5.6% 
Total 24 100.0% 36 100.0%  
 
The chi square value was 16.47 and p value was 0.05 , which implies patients 
with abnormal thyroid profile develop more complications compared to 
patients with normal thyroid profile. 
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Table 7: TREATMENT AMONG COMPLICATION 
 
Treatment No. of women % 
Adequate 5 20.8% 
Not adequate 19 79.2% 
Total 24 100.0 
 
                                                         Fig 7 
 
 
The chi square value is 28.3129, p value was <0.001, which was statistically 
significant. Which implies inadequately treated patients developed more 
complications compared to adequately treated patients  
 
                                                                                  
      
 Table 8: TSH, FT3 and FT4 
 
No. of 
women % 
TSH Normal 340 85.0% 
Abnormal 60 15.0% 
FT3normal Normal 289 72.3% 
Abnormal 111 27.8% 
FT4normal Normal 359 89.8% 
Abnormal 41 10.3% 
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Table 9: TSH and FT3 
 
 
TSH 
Total Normal Abnormal 
FT3 Normal 264 25 289 
Abnormal 
76 35 111 
Total 340 60 400 
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Table 10: TSH and FT4 
 
 
Abnormal thyroid profile 
Total Normal Abnormal 
FT4 Normal 318 41 359 
Abnormal 22 19 41 
Total 340 60 400 
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Table 11: Mode of Delivery 
 No. of women % 
 Forceps 22 5.5% 
LN 170 42.5% 
LSCS 199 49.8% 
Vacuum 9 2.2% 
Total 400 100.0 
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Table 12: Mode of Delivery and Abnormal Thyroid profile 
Mode of delivery 
Abnormal thyroid profile Chi square 
test Normal Abnormal 
n % n % 
 Normal 147 43.2% 23 38.3% 2=5.39 
P=0.14 (NS) LSCS 171 50.3% 28 46.7% 
Vacuum 6 1.8% 3 5.0% 
Forceps 16 4.7% 6 10.0% 
 Total 340 100.0% 60 100.0%  
 
                                                         Fig 12 
 
 
                                                                                  
 
Table 13: Birth weight 
 No. of babies % 
 <2.5 kg 9 2.3% 
2.5 -3.0 kg 192 48.0% 
3.0 -4.0 kg 199 49.8% 
Total 400 100.0 
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Table 14: Birth weight and Abnormal Thyroid profile 
Birth weight 
Abnormal thyroid profile Chi square 
test Normal Abnormal 
n % n % 
 <2.5 kg 8 2.4% 1 1.7% 2=0.81 
P=0.66 (NS) 2.5 -3.0 kg 166 48.8% 26 43.3% 
3.0 -4.0 kg 166 48.8% 33 55.0% 
 Total 340 100.0% 60 100.0%  
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Table 15: GESTATIONAL AGE 
GA No. of women % 
 36 weeks 30 7.5% 
37 weeks 6 1.5% 
38 weeks 32 8.0% 
39 weeks 143 35.8% 
40 weeks 189 47.3% 
Total 400 100.0 
 
FIG 15 
 
 
 
 
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16 
 
Table 16: GA and Abnormal thyroid profile 
 
Normal Abnormal  
n % n % 
 36 weeks 24 7.1% 6 10.0% 2=26.40 
P=0.001 (S) 37 weeks 4 1.2% 2 3.3% 
38 weeks 19 5.6% 13 21.7% 
39 weeks 119 35.0% 24 40.0% 
40 weeks 174 51.2% 15 25.0% 
 Total 340 100.0% 60 100.0%  
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Table 17: Obstetrical code 
 No. of women % 
 Primi 243 60.80% 
G2P1L1 77 19.30% 
G2A1 47 11.80% 
G3P2L0 16 4.00% 
G3P2L1 6 1.50% 
G3A2 4 1.00% 
G4P3L3 3 0.80% 
G2P1L0 2 0.50% 
G3P2L2 2 0.50% 
Total 400 100.0 
                                                                                  
 
Table 18: Obstetrical code and Thyroid profile 
 
Obs code 
Abnormal thyroid profile Chi square test 
Normal Abnormal 
n % n % 
 Primi 208 61.20% 35 58.30% 2=30.83 
P=0.001*** G2P1L1 61 17.90% 16 26.70% 
G2A1 45 13.20% 2 3.30% 
G3P2L0 15 4.40% 1 1.70% 
G3P2L1 5 1.50% 1 1.70% 
G4P3L3 3 0.90% 0 0.00% 
G2P1L0 2 0.60% 0 0.00% 
G3A2 1 0.30% 3 5.00% 
G3P2L2 0 0.00% 2 3.30% 
  340 100.0% 60 100.0%  
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Table 19: AGE DISTRIBUTION 
Age No. of women % 
 < 20 years 57 14.2% 
21 -25 years 165 41.3% 
26 -30 years 136 34.0% 
> 30 years 42 10.5% 
Total 400 100.0 
 
                                                     Fig19 
 
Mean age women =25.33 years and Standard deviation=4.37 years  
 
                                                                                  
 
Table 20: AGE GROUP AND THYROID PROFILE 
Age 
Abnormal thyroid profile Chi square test 
Normal Abnormal 
n % n % 
 < 20 years 52 15.3% 5 8.3% 2=15.36 P=0.01** 
21 -25 years 147 43.2% 18 30.0% 
26 -30 years 113 33.2% 23 38.3% 
> 30 years 28 8.2% 14 23.3% 
 Total 340 100.0% 60 100.0%  
 
                                               Fig 20 
 
 
                                                                                  
 
Table 21: PREVALENCE OF THYROID DYSFUNCTION 
 
Total 
screened 
Thyroid 
abnormal 
% of 
abnormality 
95%Confidence 
interval 
400 60 15.00% 13.21% -16.79% 
 
Incidence of Thyroid dysfunction is 15.00%.   95% CI shows incidence 
can lie between minimum of 13.21% to maximum of 16.79%. Also we can say 
1 out of 7 women screened cases are abnormal thyroid dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                  
 
RESULTS 
     In the study, total of 400 patients were screened. 
         The average age of women was 24 years. The average gestational age at 
time of screening was 7-9 Weeks.   243 were nullipara, 157 were multipara. 35 
of the Primi and 25 patients of multi had abnormal thyroid profile. 
There were 100 high risk cases and the remaining 300 were normal cases.  
            Of the screened population, 60 patients had abnormal thyroid profile. 
Of which 34 had subclinical hypothyroidism, 16 had overt hypothyroidism,6 
had subclinical hyperthyroidism, 4 had overt hyperthyroidism .Of these 60 
patients, 38 had risk factors, 22 had no risk factors. If high risk strategy for 
screening was used, we would miss these 22 patients, which approximates to 
one third of patients 
The chi square value was 247.334 and p value was less than 0.001 
which is statistically significant. 
        In regard to TSH, 10 patients had TSH less than 0.1, 340 had TSH 1 to 3, 
16 patients had TSH 3 to 5, 24 patients had TSH 5 to 10, 10 patients had TSH 
> 10. 
             Of the screened population, 60 patients had complications out of 400 , 
of which 24 patients had abnormal thyroid profile. Of these 24, 2 had missed 
abortion, 4 had PIH, 4 had IUGR, 6 had oligohydramnios, 4 had preterm, 2 
                                                                                  
abruption, 2 had IUD. The remaining patients with normal thyroid profile (. 
36) had complication like Oligo (8) , preterm11) , IUD 2 . GDM 4, PIH 6 , 
abruption, 2 polyhydramnios . The incidence of complications was more in 
patients with abnormal thyroid profile.  
       With regard to mode of delivery of the screened Population, 90 had 
elective LSCS, 109 had emergency LSCS, 170 had normal vaginal delivery, 22 
forceps and 9 vacuum. In amongst the abnormal thyroid profile group, 15had 
elective LSCS, 13 had emergency LSCS, 23 normal vaginal delivery, 6 
forceps, 3 vacuum. The main indication for LSCS was fetal distress, CPD, 
failed induction. 
      Of the 24 patients with complications, 5 had adequate treatment, 19 had 
inadequate treatment. Adequate treatment had 1 PIH, 1 IUGR, 2 
oligohydramnios and 1 preterm. Inadequate treatment group had 3 PIH, 3 
IUGR, 4 oligohydramnios, 3 preterm, 2 abruption, 2 IUD,2 missed abortion .  
      It was seen that out of 38, 6 Women were already having symptoms of 
thyroid disease. 5 Were obese. 6 Had history of thyroid disorders in first 
degree relative.  5 Had history of residence in hilly areas.  7  Had history of 
recurrent miscarriage, preterm delivery, history of infertility, 5 had history of 
autoimmune disorders, 4 had advanced age. 
   However 22 Patients had no high risk factors. So if we screen only high 
risk population we would miss all these cases.  
 
                                                                                  
  Of the 60 patients, 24 patients had adverse perinatal outcome. This 
shows statistically significant association between abnormal TSH values with 
adverse pregnancy outcome. And inadequately treated patients had more 
complications compared to adequately treated patients.  
          In the screened population 30 patients had preterm labour  out of which 
6belonged to the abnormal thyroid profile group.  . There was one preterm 
fresh still born in hypothyroid group. 
 This study shows significant association between abnormal TSH values 
and adverse perinatal outcome. 
                                                                                  
DISCUSSION 
The high-risk case finding approach for thyroid dysfunction, would 
therefore overlook about one out of every three pregnant women suffering 
from these thyroid disorders. The results of my study were similar to Vaidya et 
al study . The upper limit of TSH had been lowered from 0.5 to 0.1mIu/L, 
based on the 2012 endocrine society guidelines.  
The mean gestational age in this study was 9 weeks which was similar 
to the Dave et al study.  
The total population screened in this study was 400 pregnant patients, 
compared to 353 patients in nazourpur et al study and 305 patients in Dave et 
al study. The Vaidya et al study had a population of 1560. 
An ongoing Debate is about the need for universal screening of thyroid 
dysfunction in pregnancy. . Even though there is not much of sufficient 
evidence  to prove  that  the finding out  and treating  of pregnant women with 
subclinical hypothyroidism improved maternal and fetal  outcomes, the low 
cost treatment and widespread availability of screening test is now causing the 
universal screening approach an increasing popularity(7) 
In this study, we found that when potential risk factors for thyroid 
disease are used, case finding misses 25 percent of those with 
hyperthyroidism, 43.8% of those with overt hypothyroidism or 32.3 % of those 
                                                                                  
with subclinical hypothyroidism. The results were similar to the Vaidya et al 
study . 
 In the current study, the average age was. 24 years, which differed to 
that (30.8±4.7 years) of the Ohashi et al. study and 23.79 years in the Rajesh et 
al study.  This study shows a  high prevalence of undetected thyroid disorders 
during pregnancy .In addition, these variations may be due to the differences in 
the iodine  status of various areas , because in the areas with severe iodine 
deficiency resulting in a higher prevalence of goiter,  so more women had the 
risk factor required for being eligible for the case targeted high-risk case 
finding approach. Dhanwant et al discovered that 14.3% women attending a 
tertiary hospital , Delhi had hypothyroidsm and majority had subclinical 
hypothyroidism, and in my study it was 12.5 %. The Bandela et al study from 
Andhrapradesh had an incidence of subclinical hypothyroidism as 10 % , and 
the Gayathri et al study showed a prevalence of 2.8%. 
         Hyperthyroidism was much less common than hypothyroidism. The 
frequency of Overt hyperthyroisdism  is relatively low (1% in my study) which 
was similar, but higher compared  to the prince et al study in Asian women 
which showed a prevalence of 0.02%. 
      There was significant association of thyroid disorders with high risk 
factors( p<0.001). The patients with abnormal thyroid profile had adverse 
outcomes compared to those with normal thyroid profile (p<0.001) The 
                                                                                  
findings of my study were similar to Dave et al study in Madhya Pradesh, 
Negro et al study , and Vaidya et al study  
There is no consensus regarding the risk factors that had  to be included 
in a case finding approach. While American Thyroid Association and 
European societies guidelines considered age≥ 30 years as one of the risk 
factor and suggested screening all women who were  over the age of 30 years, 
there is not enough evidence on the association between the  age of patient and 
abnormal thyroid function (13) It had been shown that the inclusion of women 
who were over age ≥30 years increased the number  of pregnant women 
identified in a case finding approach from 55.3 to 85.6%  It was due to wide 
differences in the prevalence of these risk factors in various communities (10), 
thyroid screening there policies must hence be  evidence-based for each county 
and society  
The present study showed that considering the relatively low prevalence 
of risk factors among South Indian pregnant women, about  one-third of 
pregnant women with thyroid dysfunction (35.6%) were being overlooked by 
not using universal screening approach . But, those overlooked mainly were 
subclinical thyroid disorders (34.4%, n=174).  The present data on the impact 
of treating these women are limited and conflicting. While some studies 
showed  that subclinical hypothyroidism resulted in adverse pregnancy 
complications (3,) and  with L-thyroxine treatment (L-T4)prevented the 
adverse complications( 8),  this has not been showed  by others( 9). 
                                                                                  
The present study shows that among the risk factors for thyroid 
dysfunction, age, recurrent abortions and family histories of thyroid disorders, 
symptoms of thyroid disorders are significant prognostic factors for prediction 
of thyroid dysfunction. Pregnant women with recurrent abortion had more 
chance of having thyroid dysfunction, than those without this history, and a 
person with a family history of thyroid disorders had higher chance of having 
thyroid dysfunction compared to women without this history. . 
The main strength of my study was the methodology, because it is a 
study conducted mainly on pregnant Indian women in their first trimester. 
Detailed  Thyroid function assessment including history, general examination , 
and thyroid function tests were done for all study participants, while in some 
other studies these have not been done  for all participants (4). However, the 
results of our study cannot be generalized to other areas with different statuses 
of iodine sufficiency or other underlying risk factors. 
       However there are a few studies which have argument against universal 
screening. To date only 2 studies are there which have different results. The 
negro et al study found no difference in adverse outcome between universal or 
selective screening patients . However comparison of women identified with 
thyroid dysfunction during pregnancy and treated had few adverse outcomes 
than women with thyroid dysfunction who were not identified and treated.  
The Lazarus et al study showed no benefit of treatment of subclinical 
hypothyroid patients. But the pope et al study showed maternal freeT4 less 
                                                                                  
than 10 tsh entitle is associated with poorer neuropsychological performance 
than children whose maternal FT4 was more than tenth centipede. 
Thus in conclusion, targeted high-risk case finding approach surely 
overlooked about one-third proportions of pregnant women who had of thyroid 
dysfunction. While universal screening for thyroid diseases in pregnancy 
seems to be really reasonable  on considering the low cost of  treatment and 
widespread availability of screening test, but as current data on the impact of 
treating subclinical hypothyroidism are very much  limited and also 
conflicting, it cannot yet be recommended with certainty but it may be done if 
resources are sufficient.  If ongoing prospective trials provide evidence on the 
efficacy of treating subclinical hypothyroidism in pregnancy, the targeted 
high-risk case finding approach will be proven inefficient, especially in 
populations with a low prevalence of presumed risk factors. But in areas with 
high proportion of Thyroid dysfunction like India, and where government 
offers free Thyroid function testing and treatment of Thyroid disorder, it can 
surely be recommended and done in our government institutions.  
 
 
 
 
                                                                                  
 
 
CONCLUSION 
 
From this study we can infer that universal thyroid screening is much 
better than targeted case finding which misses Around  one third of patients 
with abnormal Thyroid profile.The incidence of complications was more in 
patients with abnormal thyroid profile compared to those with normal thyroid 
profile.  Identifying and Treating Thyroid dysfunction improves neonatal and 
maternal outcome. Moreover the cost of treatment is also reasonable.  Hence 
In a country where the prevalence of thyroid is high, universal screening must 
be recommended.  
                                                                                  
PROFORMA FOR UNIVERSAL THYROID SCREENING IN 
PREGNANCY VS TARGETED CASE FINDING APPROACH 
 NAME  
 Age   
 Address   
  
Op/ip number  
 Socioeconomic status  
  
Obstetric code  
 LMP  
 EDD 
 Gestational age  
 Menstrual history: regular/ irregular  
 Martial history: consanguineous/ non consanguineous  
 
 Obstetric history:  
 
 Past history: of thyroid/ GDM/ PIH /chronic HT/ autoimmune disorders,  
 Family history:  
  
 
                                                                                  
General examination  
Height                            Weight.                    BMI 
Pallor                   Icterus.               Clubbing.               Lymphadenopathy  
Visible thyroid swelling                 Eye signs             Hair  
 CVS                                                       BP.                        PR  
RS  
 Obstetric examination  
 Thyroid function test screening result        TSH.             FT3.              FT4 
 Management:  treatment if any, given:     Eltroxin         PTU 
  
Investigations.    CBC        Rbs.        Rft.         Urine routine 
  
Maternal outcome: delivered at term/ preterm/ post EDD  
  
Mode of delivery: LN.     LScs (elective/ emergency)     Vacuum.   Forceps  
 Maternal complications: Aph.     PPH      Malpresentation.   
  
Fetal outcome: alive/ stillborn/ IUD            Birthweight.          Apgar  
  
Birth asphyxia.       IUGR           Thyroid anomalies in foetus 
    Neurodevelopment delay.        Cretinism. 
 
                                                                                  
 
CONSENT FORM 
 
I, Mrs.________________________________ aged ________ years have been 
adequately well explained in the language that I understand regarding the 
clinical screening and blood investigations that are to be carried out with me. 
The purpose of the study was explained to me prior to this study being done in 
detail. I understood that the confidentiality will be maintained regarding 
identity. I have been well explained and willing to undergo oral thyroxine 
supplementation therapy. After understanding the basis of this study, I give my 
full consent to the study.  
 
 
Name of the patient:     Signature of the patient:  
Date and Time:  
 
Name of the investigator :    Signature: 
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LIST OF ABBREVATIONS 
 
TSH   Thyroid Stimulating Hormone 
T3.      Tri iodo thyronine 
T4         Tetra iodo thyronine 
HCG.     Human Chorionic Gonadotropin 
Wks.     Weeks 
PIH        Pregnancy induced hypertension 
IUGR.    Intra uterine growth restriction 
NVD.       Normal vaginal delivery 
LSCS.      Lower segment caesarean section  
PPROM  Preterm premature rupture of membranes 
PROM     Premature rupture of membranes 
LBW        Low birth weight 
Rx             Treatment  
GDM       Gestational diabetes mellitus 
 HTN.          Hypertension 
                                                                                  
  
S . 
No Name Age Op no Obs code
High 
risk GA TSH FT3 FT4 Mode Bwt Ga Compli Adequate rx
1 Limina 19 47385 Primi Yes   9 weeks 4 2 9  Over hpo  Elt 50 Lscs 3.2 38
2 Tharangini 18 49357 Primi Yes 7weeks 3 4 11 Sch  Forceps 3.4 39 Oligo No
3 Renuka 16 43962 Primi No 9weeks 5 1 8 Overt hpo Vacuum 3.4 38
4 Sudha 19 43974 Primi Yes 6weeks 0.01 9 18 Ov hypr Ptu 100 TDS LN 2.6 39 Mis abr No
5 Chandra 17 43267 Primi No 7 weeks 4 5 12 Sch Elt 25 mic Lscs 2.6 38
6 Raji 18 10216 Primi Yes 8 weeks 0.02 4 12 Sc hpr Elt  50 Ln 2.9 39
7 Muthu 17 10022 G2A1 Yes 11 weeks 5 6 13 Sch Lscs 2.7 37 IUGR No
8 Radhika 21 51968 Primi Yes 9 weeks 3 1 7 Ov hypo Forceps 3.4 38 IUGR No
9 Nafis 22 43675 G3A2 Yes 8 weeks 3 4 14 Sc hpo Elt 25 Lscs 3.5 38 Oligo 
10 Meenu 22 43699 Primi No 9 weeks 6 2 6 Ov hpo Elt  50 Lscs 3.5 39 Abruption No
11 Abirami 23 43678 Primi Yes 8 weeks 4 5 15 Sc hpo Elt  50 Vacuum 3.1 38
12 Tharangini 24 43566 G2P1L1 No 9 weeks 0.03 11 20 Ov hpr Ptu 100 TDS LSCS 2.9 39 Oligo
13 Saira 25 43555 G2P1L1 Yes 10 weeks 5 6 16 Sc hpo Elt  50 Vacuum 2.6 39
14 Divya 24 43567 Primi No 8 weeks 5 1 7 Ov hypo Elt  50 LSCS 3.5 39
15 Ramya 21 57863 G2P1L1 Yes 10 weeks 6 7 11 Sch Elt  50 Forceps 3.1 38 Pih No
16 Vidhya 22 57864 Primi Yes 9 weeks 0.04 5 12 Sc hpr Lscs 2.9 38 Oligo No
17 Priya 22 32456 Primi No 10 weeks 3 4 12 Sch Elt  50 Lscs 2.6 39
18 Rasiga 25 57865 Primi Yes 9weeks 4 2 6 Ove hypo Elt 75 Forceps 3.5 39 Mis abo No
19 Mathi 25 57868 Primi Yes 10 weeks 4 5 13 Sch Elt 25 Lscs 2.9 38 Oligo 
20 Nachiyar 24 54673 Primi No 8 weeks 5 6 15 Sch Elt 25 Ln 2.9 39
21 Anandhi 25 57865 G3A2 Yes 10 weeks 3 1 9 Ov hypo Elt  50 LSCS 3.1 40 IUGR 
22 Anbu 25 57846 Primi No 9 weeks 6 7 14 Sch Elt  50 LN 2.6 36 Iud No
23 Ranjani 26 57864 G2P1L1 Yes 8 weeks 3 5 16 Sch Elt 25 LSCS 3.5 40 Pih No
24 Kiritha 27 57846 Primi No 9 weeks 4 4 11 Sch Elt 25 LN 2.9 39
25 Duri 27 54678 G3P2L2 Yes 10 weeks 5 0.5 8 Ov hpo Elt 75 Ln 3.1 40 Oligo
26 Durga 26 57896 Primi No 8 weeks 5 6 12 Sch Elt  50 LSCS 2.6 39 Preterm No
27 Deepa 27 57899 G2P1L1 Yes 9 weeks 6 7 14 Sch Elt  50 Ln 2.9 40
28 Shakthi 28 57654 Primi Yes 10 weeks 0.06 13 23 Ov hypr Ptu 100 TDS LSCS 3.5 40 Oligo No
29 Akshaya 28 32456 Primi No 10 weeks 3 4 13 Sch Elt 25 Ln 2.5 40
30 Anusha 28 57832 Primi No 8 weeks 0.05 6 13 Sc hpr LSCS 3.1 39 Preterm No
31 Akila 29 34765 G2P1L1 Yes 10 weeks 4 5 16 Sch Elt  50 LN 2.7 36
32 Afsana 28 65432 Primi Yes 9 weeks 5 6 12 Sch Elt  50 Ln 3.5 39
33 Banu 27 61356 Primi Yes 10 weeks 6 0.5 7 Ov hypo Elt 75 LSCS 2.8 39 Pih No
34 Sowmya 28 65723 Primi No 8 weeks 6 7 11 Sch Elt 75 Ln 3.1 38
35 Soundarya 27 56432 Primi Yes 10 weeks 3 4 13 Sch Elt  50 LSCS 3.2 39
36 Nithya 27 43567 Primi Yes 9 weeks 5 1 9 Ov hypo Elt  50 Ln 3.5 39 Oligo No
37 Anusiri 26 54367 Primi Yes 8 weeks 4 5 14 Sch Elt 25 LSCS 3.5 39 Iugr
38 Karthiga 26 56432 Primi No 10 weeks 0.05 5 13 Sc hpr Ln 2.9 50
39 Meenaksi 28 43215 Primi Yes 9 weeks 5 6 16 Sch Elt  50 LSCS 3.5 40 Oligo
40 idevi 28 54678 Primi No 10 weeks 6 2 8 Ov hypo Elt 100 Ln 3.5 36 Abruption No
41 Punitha 28 54123 Primi Yes 8 weeks 6 7 12 Sch Elt  50 Ln 3.5 40
42 Prema 29 54673 G2P1L1 Yes 10 weeks 3 4 13 Sch Elt 25 LSCS 3.1 39
43 Meena 29 53214 Primi No 9 weeks 0.06 6 12 Sc hpr Ln 3.5 39
44 Rina 30 76542 G3A2 Yes 10 weeks 7 0.5 7 Ov hpo Elt 100 LSCS 2.9 39 Iud No
45 Kamatchi 30 65786 Primi No 9 weeks 4 5 15 Sch Elt  50 LN 2.9 40
46 Jeya 29 67543 G2P1L1 Yes 8 weeks 5 6 16 Sch Elt 100 LSCS 3.1 38 Preterm No
47 Selvi 31 54376 G3P2L2 Yes 10 weeks 5 0.5 14 Ov hpo Elt 75 Ln 2.6 39 Preterm 
48 Indira 33 45321 Primi No 10 weeks 6 7 11 Ov hpr Elt 75 LSCS 3 39 Miss abo No
49 Rathi 34 65437 G2P1L1 Yes 9 weeks 3 4 12 Sch Elt 25 LSCS 2.6 40
50 Nirmala 35 87654 Primi No 8 weeks 0.07 5 14 Ov hypr Ptu 100 TDS LN 2.9 39
51 Aruna 36 75436 Primi Yes 10 weeks 4 6 13 Sch Elt 75 LSCS 3.1 40
52 Athithi 35 56743 Primi Yes 10 weeks 8 0.2 14 Sch Elt 100 LSCS 3 38 No
53 Aranya 34 46731 G2P1L1 No 9 weeks 5 7 15 Sch Elt 100 LN 2.6 40
54 Nikitha 32 87432 G2P1L1 Yes 8 weeks 6 4 15 Sc hpr LSCS 3.1 38 Preterm 
55 Manu 33 43521 G2P1L1 No 10 weeks 3 5 16 Sch Elt  50 LN 3.3 39
56 Janani 33 76543 G2P1L1 No 9 weeks 0.04 6 12 Sc hpr Ptu 100 TDS LSCS 2.9 39
57 Dharshini 32 54765 G2P1L1 Yes 10 weeks 4 7 14 Sch Elt 75 LSCS 3 40
58 Sara 33 45322 Primi No 10 weeks 7 1 3 Ov hpo Elt 75 LSCS 3.1 39 Pih
59 Jenny 32 45367 G2P1L1 Yes 9 weeks 5 4 13 Sch Elt 25 Ln 2.6 39 I
60 Nivetha 32 45333 G2P1L1 Yes 9 weeks 6 2 7 Ove hypo Elt 50 Ln 2.8 39 Pih
61 Nandhini 33 45377 Primi No 8 weeks 1 3 11 Normal Vacuum 2.6 40
62 Nancy 19 43256 G3A2 No 8 weeks 1.3 3.1 15 Normal LSCS 3.2 39
63 Tara 26 41758 Primi No 9 weeks 0.9 4.2 15.7 Normal LN 3.4 40
64 Rita 27 41759 Primi No 8 weeks 1.5 5 16.7 Normal LN 3.4 36 Preterm 
65 Tina 19 43215 Primi No 7 weeks 1.1 3.8 15.7 Normal LN 3 40
66 Linda 21 43216 G2P1L1 No 9 weeks 0.7 3.5 16 Normal LN 2.6 39
67 Hasina 28 43217 Primi No 10 weeks 2 4.7 11.1 Normal LN 2.9 40
68 Jaseema 22 43218 Primi No 8 weeks 1.8 5.4 11 Normal LSCS 2.7 39
69 Fatima 19 54321 G2P1L1 No 7 weeks 0.9 3.5 11.5 Normal LN 3.4 40
70 Hasna 23 43219 Primi No 9 weeks 1.2 4.9 12.5 Normal LN 3.5 40
71 Linsu 28 43220 Primi No 9 weeks 0.7 5.2 12.6 Normal LN 3.5 40
72 Navya 24 51769 Primi No 7 weeks 2 4,8 16 Normal LSCS 3.1 39
73 Keerthi 19 32146 G2P1L1 No 10 weeks 2.3 3.1 15.6 Normal LN 2.9 36 Preterm
74 Kavya 21 43221 Primi No 9 weeks 1.3 4.7 14.5 Normal LN 2.6 39
75 Rani 22 45670 Primi No 8 weeks 2.2 3.8 14.6 Normal LN 3.5 39
76 Sindhu 28 43222 Primi No 10 weeks 0.9 4.7 15.6 Normal Vacuum 3.1 38
77 Lakshmi 23 45671 Primi No 9 weeks 2 4.2 14.6 Normal LN 2.9 39 Oligo
78 Seetha 19 54367 Primi No 8 weeks 0.7 4.1 13.5 Normal LN 2.6 39
79 Rekha 24 45672 Primi No 7 weeks 1.3 4.6 13.9 Normal LSCS 3.5 39
80 Sasi 24 67543 Primi No 9 weeks 1.2 5 15 Normal LN 2.9 50
81 Shantha 27 54369 G2P1L1 No 8 weeks 2.3 4.9 15.7 Normal LSCS 2.9 40
82 Chitra 23 67545 G2A1 No 7 weeks 1.5 3.3 16 Normal LN 3.1 40
83 Saritha 19 54377 Primi No 10 weeks 2.2 3.6 16 Normal LN 2.6 39
84 Geetha 22 67532 Primi No 7 weeks 2 6.6 15.4 Normal LSCS 3.5 38
85 Gowri 27 67554 Primi No 9 weeks 1.8 3.9 14.6 Normal LN 2.9 40
86 Reema 21 47865 Primi No 8 weeks 1.2 3.5 15.1 Normal LN 3.1 40 Pih
87 Kalpana 18 65789 G2P1L0 No 10 weeks 0.8 6.8 12.5 Normal Vacuum 2.6 36
88 Megha 23 47876 Primi No 9 weeks 1.8 6.5 15 Normal LN 2.9 39
89 Ishwarya 22 54322 G2P1L1 No 8 weeks 0.7 6.4 15.7 Normal LN 3.5 38
90 Isha 24 51788 Primi No 7 weeks 1.7 3.5 16.7 Normal LN 2.5 40
91 Asha 18 56744 Primi No 10 weeks 0.9 5.4 15.7 Normal LN 3.1 40
92 Sathya 27 51789 Primi No 9 weeks 1.2 6.5 16 Normal LSCS 2.7 40
93 Vidhya 25 51790 Primi No 8 weeks 1.3 4.7 11.1 Normal LN 3.5 38 Oligo 
94 Thangam 19 56749 G2A1 No 6 weeks 0.8 3.1 11 Normal LN 2.8 40
95 Baby 24 51791 Primi No 9 weeks 1.5 5.8 11.5 Normal LN 3.1 39
96 Sofia 19 56749 Primi No 7 weeks 1.8 4 12.5 Normal LN 3.2 40
97 Mala 23 51792 Primi No 8 weeks 2.2 5.9 12.6 Normal LN 3.5 38
98 Lavanya 27 65478 Primi No 9 weeks 1.2 6 16 Normal Vacuum 3.5 39
99 Manjula 22 54123 G2P1L1 No 10 weeks 2.3 5 15.6 Normal LN 2.9 36
100 Unmade I 24 65780 Primi No 8 weeks 1.3 4.2 14.5 Normal LN 3.5 40 Pih
101 Angel one 18 65478 Primi No 9 weeks 2 6 14.6 Normal LN 3.5 39
102 Uma 23 65781 Primi No 10 weeks 0.8 5 15.6 Normal LSCS 3.5 40
103 Papa 27 65745 Primi No 8 weeks 0.9 3.5 14.6 Normal LN 3.1 39
104 Vaishnavi 19 65179 G2P1L0 No 9 weeks 1.2 6.1 13.5 Normal LSCS 3.5 40
105 Kokila 25 65890 Primi No 7 weeks 0.7 6.2 13.9 Normal LN 2.9 40
106 Rosalind 24 65891 Primi No 6 weeks 1.3 3.1 12.9 Normal LN 2.9 40
107 Vinodha 28 67532 Primi No 9 weeks 0.6 5.5 15 Normal LSCS 3.1 39
108 Vanitha 23 60032 Primi No 8 weeks 2 5.8 15.7 Normal LN 2.6 38
109 Manju 22 60054 Primi No 7 weeks 0.7 5.7 16.7 Normal LN 3.5 36 Preterm
110 Roja 19 67437 G3P2L0 No 9 weeks 1.2 5.4 15.7 Normal LSCS 2.6 37
111 Nancy 23 60786 Primi No 10 weeks 2.2 5.3 16 Normal LN 2.9 40
112 Udaya 24 54789 Primi No 6 weeks 0.9 4.2 11.1 Normal LN 3.1 39
113 Surya 18 69876 Primi No 9 weeks 1.5 5.7 11 Normal LN 3 40
114 Bharati 22 54789 Primi No 8 weeks 2.3 6.6 11.5 Normal Vacuum 2.6 39
115 Surabhi 31 69842 G2P1L1 No 9 weeks 1.3 6.3 12.5 Normal LN 3.1 40
116 Dhanam 19 65432 Primi No 10 weeks 1.2 5.5 12.6 Normal LN 3.3 40
117 Nimmy 28 65478 G2P1L1 No 7 weeks 2.2 3.1 16 Normal LN 2.9 40
118 Nirmala 22 65345 Primi No 9 weeks 0.7 4.4 15.6 Normal LSCS 3 39
119 Shula 22 65437 Primi No 8 weeks 1.5 3.9 14.5 Normal LN 3.1 38
120 Rabiya 23 68972 G2P1L1 No 11 weeks 2.3 5.3 14.6 Normal LN 2.6 38 Pih
121 Monisha 18 65412 Primi No 9 weeks 2 4 15.6 Normal LN 2.8 37
122 Dharini 24 68973 Primi No 7 weeks 2 3.5 14.6 Normal LN 2.9 38
123 Yamuna 23 68974 Primi No 10 weeks 1.2 6 13.5 Normal LSCS 2.6 36 Preterm
124 Ganga 22 68975 G2P1L1 No 9 weeks 2.3 5 13.9 Normal LN 3.5 38
125 Godavari 18 65476 Primi No 8 weeks 0.7 6.7 12.3 Normal LSCS 2.9 40
126 Thulsi 24 68976 Primi No 6 weeks 1.8 5.7 13.6 Normal LSCS 2.9 39
127 Pankajam 24 68977 Primi No 9 weeks 2 3.1 14.6 Normal LSCS 3.1 40
128 Anitha 28 68979 Primi No 7 weeks 2.2 4.2 15.6 Normal LN 2.6 39
129 Suganthi 23 76512 G2P1L1 No 10 weeks 1.2 4.1 13.5 Normal LSCS 3.5 40
130 Vennila 22 70651 Primi No 8 weeks 1.3 4.6 15 Normal LN 2.9 40
131 Karmukil 19 76544 G2A1 No 9 weeks 2.3 5 15.7 Normal LN 3.1 40 Pih
132 Parkavi 23 70652 Primi No 11 weeks 1.5 4.9 16.7 Normal LN 2.6 39
133 Janani 28 70653 Primi No 10 weeks 0.7 3.3 15.7 Normal Lscs 2.9 40
134 Vasari 29 70654 Primi No 9 weeks 2.4 3.6 16 Normal LN 3.5 36 Preterm
135 Suji 18 76533 Primi No 8 weeks 1.2 6.6 11.1 Normal LN 2.5 40
136 Teresa 29 70654 G2P1L1 No 6 weeks 2.3 3.9 11 Normal LSCS 3.1 40
137 Summy  23 70655 Primi No 9 weeks 1.8 3.5 11.5 Normal LSCS 2.7 39
138 Neerja 33 76522 Primi No 11 weeks 1.3 3.5 12.5 Normal LSCS 3.5 40
139 Jennifer 29 70656 Primi No 10 weeks 2 5 12.6 Normal LSCS 2.8 39
140 Nisha 17 86433 G2P1L1 No 9 weeks 2.2 6 16 Normal LSCS 3.1 40 Oligo
141 Tamilini 29 70657 Primi No 11 weeks 1.5 3.1 15.6 Normal LSCS 3.2 40
142 Ameena 29 70859 Primi No 7 weeks 0.8 5.8 14.5 Normal LSCS 3.5 40
143 Alisha 18 73214 Primi No 9 weeks 1.8 4 14.6 Normal LSCS 3.5 39
144 Anisha 21 70956 Primi No 8 weeks 0.7 5.9 15.6 Normal LSCS 2.9 38
145 Nausheen 24 78543 Primi No 6 weeks 1.2 6 14.6 Normal LSCS 3.5 39
146 Browny 33 75347 G2P1L1 No 9 weeks 1.3 5 13.5 Normal LSCS 3.5 40
147 Prince 30 78544 Primi No 10 weeks 0.9 4.2 13.9 Normal LN 3.5 40
148 Nila 18 87623 Primi No 8 weeks 1.5 6 12.3 Normal LN 3.1 36
149 Thaslima 23 78544 G2P1L1 No 9 weeks 2 5 13.7 Normal LN 3.5 40
150 Fatima 23 78545 Primi No 11 weeks 0.8 3.5 15.1 Normal LN 2.9 40 Pih
151 Ishwarya 34 87654 G2A1 No 10 weeks 1.2 3.7 12.3 Normal LN 2.9 39
152 Divya 30 78564 Primi No 9 weeks 1.7 4.2 13.3 Normal LSCS 3.1 40
153 Nithya 18 45633 Primi No 7 weeks 1.8 4.7 13.7 Normal LSCS 2.6 39
154 Rathika 28 78564 G2P1L1 No 9 weeks 2.2 3.1 14.8 Normal LSCS 3.5 40
155 Rasiga 25 67542 Primi No 8 weeks 1.5 5.7 15 Normal LSCS 2.6 40
156 Shyamala 23 67543 G2P1L1 No 6 weeks 0.8 3.1 16 Normal LSCS 2.9 40
157 Prasana 19 67899 G3P2L0 No 9 weeks 0.7 4.2 12.3 Normal LSCS 3.1 39
158 Ratnam 24 67544 Primi No 7 weeks 2.2 4.1 13.6 Normal LSCS 3 40
159 Giridhari 34 54367 Primi No 10 weeks 2 4.6 14.6 Normal LSCS 2.6 39
160 Mirabai 23 67555 G2P1L1 No 9 weeks 1.2 5 15.6 Normal LSCS 3.1 40
161 Lakshmi 17 87345 G2A1 No 8 weeks 0.8 4.9 13.5 Normal LSCS 3.3 39
162 Kaliamal 24 67567 Primi No 6 weeks 1.3 3.3 15 Normal LSCS 2.9 36
163 Jagatha 26 67532 G2P1L1 No 9 weeks 2 3.6 15.7 Normal LSCS 3 40
164 Nancy 18 65746 Primi No 10 weeks 0.7 6.6 16.7 Normal LSCS 3.1 40
165 Uma 30 66781 G2P1L1 No 9 weeks 1.2 3.9 15.7 Normal Vacuum 2.6 39
166 Kayak 23 66782 G2P1L1 No 7 weeks 2.2 3.5 16 Normal Forceps 2.8 40 Iud
167 Jeevitha 34 46736 G2P1L1 No 8 weeks 0.9 3.5 11.1 Normal LN 2.7 39
168 Renu 17 57437 Primi No 6 weeks 1.5 3.1 11 Normal LN 2.9 40
169 Swarna 25 66783 Primi No 9 weeks 1.9 5.7 11.5 Normal LSCS 2.6 40 Pih
170 Vairam 26 66784 Primi No 11 weeks 2 3.1 12.5 Normal LSCS 3.5 40
171 Raji 24 66785 Primi No 9 weeks 2.5 4.2 12.6 Normal LN 2.9 39
172 Papa 18 76433 G2P1L1 No 8 weeks 1.2 4.1 16 Normal LN 2.9 40
173 Baby 23 66786 Primi No 9 weeks 2.3 4.6 15.6 Normal LN 3.1 39
174 Subha 26 66787 Primi No 10 weeks 1.8 5 14.5 Normal LN 2.6 40
175 Maha 30 66788 G3P2L0 No 7 weeks 2.4 4.9 14.6 Normal LN 3.5 40
176 Minu 17 87347 Primi No 9 weeks 2 3.3 15.6 Normal LN 2.9 40
177 Vilvam 22 66789 G4P3L3 No 8 weeks 2 3.6 14.6 Normal LN 3.1 36 Preterm
178 Thendral 26 70567 Primi No 9 weeks 1.3 6.6 13.5 Normal LN 2.6 40
179 Ramani 22 70568 Primi No 11 weeks 0.7 3.9 13.9 Normal LSCS 2.9 40
180 Suganya 24 70569 G2A1 No 10 weeks 2.2 3.5 15 Normal LSCS 3.5 39
181 Bharati 19 65478 G2A1 No 9 weeks 1.5 3.5 15.7 Normal LSCS 2.5 40
182 Prerna 30 65879 G2P1L1 No 8 weeks 2.4 3.5 12.4 Normal LSCS 3.1 39 Oligo
183 Yukthi 26 65870 G3P2L1 No 6 weeks 0.8 3.1 11.9 Normal LSCS 2.7 40
184 Latha 32 54673 Primi No 9 weeks 2 5.7 11 Normal LSCS 3.5 40
185 Indira 22 65871 Primi No 7 weeks 0.9 3.1 11.8 Normal LSCS 2.8 40
186 Priya 18 56732 G2P1L1 No 10 weeks 0.6 4.2 11.6 Normal LSCS 3.1 39
187 Mangala 24 65872 G2P1L1 No 9 weeks 1.2 4.1 11 Normal Ln 3.2 36 Preterm
188 Rani 27 65873 Primi No 11 weeks 0.7 4.6 13.7 Normal Forceps 3.5 40
189 Kalimal 24 65874 G3P2L1 No 9 weeks 0.8 5 14.8 Normal LN 3.5 40
190 Vani 22 65875 Primi No 10 weeks 1.8 4.9 15 Normal LN 2.9 39
191 Rani 18 65432 G2P1L1 No 8 weeks 0.8 3.3 16 Normal LN 3.5 40
192 Tina 23 60876 G4P3L3 No 9 weeks 1.3 3.6 12.3 Normal LSCS 3.5 39
193 Roshni 24 60880 Primi No 7 weeks 0.7 6.6 13.6 Normal LSCS 3.5 40
194 Karthi 27 59860 G2P1L1 No 6 weeks 1.2 3.9 14.6 Normal LSCS 3.1 40
195 Anu 30 60881 Primi No 9 weeks 0.7 3.5 15.6 Normal LSCS 3.5 40
196 Shakthi 22 59862 G3P2L0 No 11 weeks 0.9 3.5 13.5 Normal LSCS 2.9 39
197 Subba 18 67895 Primi No 10 weeks 0.8 3.1 11.8 Normal LSCS 2.9 40
198 Kaali 25 59861 G2A1 No 9 weeks 1.5 5.4 11.6 Normal LN 3.1 39
199 Devi 29 59862 Primi No 7 weeks 1.2 5.5 11 Normal LN 2.6 40
200 Dharini 24 60882 G2P1L1 No 6 weeks 1.1 6.4 13.7 Normal LN 3.5 39
201 Ramya 24 59863 G3P2L0 No 9 weeks 1.2 6.5 14.8 Normal LN 2.6 40
202 Divya 17 45763 G4P3L3 No 7 weeks 1.2 6.4 15 Normal LN 2.9 40
203 Deepa 28 59864 Primi No 10 weeks 1.3 4.2 16 Normal LN 3.1 40
204 Meenu 29 59865 Primi No 9 weeks 1.1 5.6 12.3 Normal LN 3 39
205 Nancy 28 59866 G2P1L1 No 11 weeks 2 5.7 13.6 Normal LN 2.6 38
206 Subha 30 59868 Primi No 8 weeks 0.8 6.7 14.6 Normal LSCS 3.1 36 Preterm
207 Kartika 29 60883 G2A1 No 6 weeks 1.5 6.6 15.6 Normal LSCS 3.3 39
208 Vaani 25 59867 Primi No 9 weeks 1.9 6.8 13.5 Normal LSCS 2.9 40
209 Rani 23 59869 Primi No 7 weeks 1.8 6.7 16.7 Normal LSCS 3 40
210 Priya 33 67854 G2P1L1 No 11 weeks 2.1 3.1 15.7 Normal LSCS 3.1 39
211 Saranya 24 50670 Primi No 9 weeks 1.3 7 16 Normal LSCS 2.6 40
212 Anusha 29 50672 Primi No 11 weeks 0.8 6 11.1 Normal Forceps 2.8 39
213 Abinaya 23 50671 G2P1L1 No 10 weeks 1.2 5.6 11 Normal LSCS 2.9 40
214 Aishwarya 30 60884 G2A1 No 9 weeks 1.1 4.3 11.5 Normal LN 2.6 40
215 Afsana 24 50673 Primi No 8 weeks 0.9 5.5 12.5 Normal Forceps 3.5 40
216 Apsara 29 50676 Primi No 7 weeks 2.2 4.6 12.6 Normal LN 2.9 39 Oligo
217 Ravina 24 76897 Primi No 9 weeks 1.5 3.5 16 Normal LN 2.9 38
218 Surya 23 76587 G2P1L1 No 6 weeks 2.3 6.4 15.6 Normal LN 3.1 39
219 Udaya 18 43567 G2P1L1 No 10 weeks 0.7 4.2 14.5 Normal LN 2.6 40
220 Deepika 24 67865 G3P2L1 No 9 weeks 1.8 5.6 14.6 Normal LSCS 3.5 36 Iugr
221 Dhina 30 50675 Primi No 11 weeks 1.2 5.7 15.6 Normal LSCS 2.9 40
222 Nirmala 29 60885 Primi No 7 weeks 1.8 6.7 14.6 Normal LSCS 3.1 40
223 Jeyanthi 23 67342 G3P2L0 No 9 weeks 1.8 6.6 13.5 Normal LSCS 2.6 39
224 Darshini 24 87689 Primi No 6 weeks 0.8 6.8 13.9 Normal LSCS 2.9 40
225 Tabu 23 50674 Primi No 8 weeks 2 6.7 15 Normal LSCS 3.5 39
226 Yasmin 32 54326 G3P2L1 No 7 weeks 0.7 5.6 15.7 Normal LSCS 2.5 40
227 Tahini 25 69875 G2P1L1 No 9 weeks 1.5 4.6 12.4 Normal LN 3.1 40
228 Yathindra 29 69866 Primi No 11 weeks 0.6 3.1 11.9 Normal LN 2.7 40
229 Jhansi 23 60886 G2A1 No 8 weeks 2 6.4 11 Normal LN 3.5 39
230 Ranjini 22 69877 Primi No 10 weeks 2.2 4.2 11.8 Normal LN 2.8 39
231 Keerthi 32 54367 G2P1L1 No 9 weeks 2.4 5.6 11.6 Normal Forceps 3.1 40
232 Kamini 23 69888 G2A1 No 11 weeks 1.2 5.7 14.8 Normal LN 3.2 39 Gdm
233 Thangam 28 50678 Primi No 7 weeks 1.5 6.7 15 Normal LN 3.5 40
234 Soundarya 30 68977 Primi No 6 weeks 2.4 6.6 16 Normal LSCS 3.5 40
235 Ahalya 24 67543 G2A1 No 9 weeks 2.5 6.8 12.3 Normal LSCS 2.9 38
236 Anitha 23 50699 Primi No 8 weeks 1.5 6.7 13.6 Normal LSCS 3.5 39
237 Abitha 18 54673 G2P1L1 No 11 weeks 0.8 3.5 14.6 Normal LSCS 3.5 36 Preterm
238 Abira 23 65487 Primi No 10 weeks 0.9 5.6 15.6 Normal LSCS 3.5 39
239 Anandha 24 60887 G3P2L1 No 9 weeks 2.5 4.2 13.5 Normal LSCS 3.1 40
240 Ankitha 28 63214 Primi No 7 weeks 1.2 4.1 15 Normal LSCS 3.5 39
241 Advaitha 24 63217 G2P1L1 No 6 weeks 0.7 4.6 14 Normal LN 2.9 40 Gdm
242 Ananya 32 54678 Primi No 9 weeks 1 5 12 Normal LN 2.9 40
243 Bharathi 30 63219 G2A1 No 8 weeks 1.8 4.9 14 Normal LN 3.1 40
244 Bhuvana 25 63330 Primi No 11 weeks 1.3 3.3 15 Normal Forceps 2.6 39
245 Shakthi 28 63331 G2P1L1 No 9 weeks 1.1 3.6 15 Normal LN 3.5 40
246 Abinaya 24 60888 Primi No 7 weeks 2.5 6.6 16 Normal LN 2.6 36 Preterm
247 Jency 30 63334 Primi No 10 weeks 1.2 3.9 14.4 Normal LN 2.9 40
248 Vency 25 56784 G2P1L1 No 9 weeks 2 3.5 13.6 Normal LN 3.1 39
249 Kalyani 31 54678 G2P1L1 No 8 weeks 1.5 4 12.5 Normal LSCS 3 40
250 Bhavana 24 56754 Primi No 11 weeks 2.4 6 14.5 Normal LSCS 2.6 39
251 Kamini 28 56743 G3P2L1 No 9 weeks 1.4 5 13.6 Normal LSCS 3.1 40
252 Ravina 30 60889 Primi No 11 weeks 2 3.1 13.5 Normal LSCS 3.3 40
253 Rajama 23 76523 Primi No 10 weeks 2.3 6 13.7 Normal LSCS 2.9 40
254 Ranjitha 19 43267 G2P1L1 No 7 weeks 1.2 4 14.8 Normal LSCS 3 39
255 Bavya 22 87435 G2A1 No 9 weeks 2.2 7 15 Normal LSCS 3.1 40
256 Asha 28 87907 Primi No 8 weeks 2.1 5 16 Normal LSCS 2.6 39
257 Varsha 30 89076 Primi No 6 weeks 1.4 3.5 12.3 Normal LSCS 2.8 40
258 Fahima 22 56788 G3P2L0 No 10 weeks 1 3.2 13.6 Normal LSCS 3.1 38
259 Fairoz 32 54673 Primi No 9 weeks 2.5 5.6 14.6 Normal LSCS 2.9 37 Abruption
260 Deepa 22 56890 Primi No 7 weeks 1.8 4.2 15.6 Normal LSCS 2.6 38
261 Zeba 30 56891 G3P2L0 No 11 weeks 2.5 4.1 13.5 Normal LN 3.5 36
262 Meena 23 56892 Primi No 8 weeks 1.2 4.6 12.5 Normal LN 2.9 40
263 Mona 23 56893 G2P1L1 No 9 weeks 0.7 5 15 Normal LN 2.9 39
264 Radha 27 56894 Primi No 6 weeks 2.4 4.9 16 Normal LN 3.1 40
265 Nivetha 24 78905 G2P1L1 No 1.5 3.3 12.3 Normal Forceps 2.6 39
266 Nandhini 23 78906 Primi No 9 weeks 2.5 3.6 13.6 Normal LN 3.5 40
267 Nafis 33 54216 Primi No 8 weeks 2 6.6 14.6 Normal LN 2.9 40
268 Nancy 24 78904 G2P1L1 No 7 weeks 2.1 3.9 15.6 Normal LN 3.1 40
269 FAthima 23 78906 Primi No 9 weeks 1.2 3.5 16 Normal LN 2.6 39
270 Mohamada 28 76578 G2P1L1 No 11 weeks 0.8 3.5 12.3 Normal LSCS 2.9 40
271 Priyanka 21 76890 Primi No 10 weeks 0.9 4.2 13.6 Normal LSCS 3.5 36 Preterm
272 Kalpana 30 76896 Primi No 11 weeks 1.4 5.7 14.6 Normal LSCS 2.5 40 Oligo
273 Preethi 32 65784 G2A1 No 9 weeks 0.7 6.6 15.6 Normal LSCS 3.1 39
274 Sanjana 33 54678 Primi No 6 weeks 0.9 6.3 14.8 Normal LSCS 2.7 40
275 Jaya 23 78954 Primi No 8 weeks 1.5 5.5 15 Normal LSCS 3.5 39
276 Vasantha 24 78905 Primi No 7 weeks 1.8 3.1 16 Normal LN 2.8 40
277 Prema 28 78666 G2A1 No 9 weeks 0.7 4.4 12.3 Normal LN 3.1 40
278 Ravina 25 78906 Primi No 11 weeks 1.4 3.9 13.6 Normal Forceps 3.2 40
279 Divya 23 76884 Primi No 8 weeks 1.2 5.3 14.6 Normal LN 3.5 39
280 Deborah 30 67879 G2P1L1 No 9 weeks 0.9 4 15.6 Normal LN 3.5 40
281 Diana 24 87659 Primi No 11 weeks 0.8 3.5 13.5 Normal LN 2.9 40
282 Iswarya 29 89765 G3P2L0 No 10 weeks 2 6 14 Normal LSCS 3.5 39
283 Rani 23 87695 Primi No 11 weeks 0.7 5,3 14.5 Normal LSCS 3.5 36 Preterm
284 Kanimozhi 24 89087 G3P2L0 No 9 weeks 2 6 12.7 Normal LSCS 3.5 39
285 Kavya 30 45765 Primi No 7 weeks 1 3.1 12.6 Normal LSCS 3.1 39
286 Ramya 23 78905 G2A1 No 8 weeks 1.5 4.2 12.5 Normal LSCS 3.5 40
287 Yazhini 24 67856 G2P1L1 No 6 weeks 1 4.1 15.6 Normal LSCS 2.9 39
288 Priya 28 67895 Primi No 9 weeks 0.7 4.6 15 Normal LSCS 2.9 40
289 Malini 25 67890 Primi No 11 weeks 1.1 5 14 Normal LSCS 3.1 39
290 Vidhya 30 78965 G2P1L1 No 8 weeks 1.2 4.9 12 Normal LSCS 2.6 40
291 Mahima 24 78906 G3P2L0 No 11 weeks 1.1 3.3 14 Normal LSCS 3.5 40
292 Lakshmi 28 78965 Primi No 9 weeks 1.8 3.6 15 Normal LSCS 2.6 40
293 Maha 25 70986 Primi No 7 weeks 2.2 6.6 15 Normal LSCS 2.9 39
294 Yamini 23 56789 G3P2L0 No 10 weeks 0.7 3.9 16 Normal LN 3.1 38
295 Priya 24 76545 Primi No 9 weeks 1.5 3.5 14.4 Normal LN 3 39
296 Deepa 29 76854 Primi No 6 weeks 1.3 5 13.6 Normal Forceps 2.6 40
297 Rupa 24 78954 G2A1 No 8 weeks 2 4.2 12.5 Normal LN 3.1 40
298 Ramya 30 78655 Primi No 9 weeks 0.9 5 14.5 Normal LN 3.3 36 Abruption
299 Preethy 33 54674 G2A1 No 7 weeks 1.2 5 13.6 Normal LSCS 2.9 40
300 Rani 23 78644 G3P2L0 No 11 weeks 1.3 5 13.5 Normal LSCS 3 39
301 Anusha 22 67899 Primi No 9 weeks 1.4 3.5 13.7 Normal LSCS 3.1 40
302 Sasirehka 27 69987 Primi No 8 weeks 1 3.3 14.8 Normal LSCS 2.6 40
303 Jancy 22 69987 G2P1L1 No 10 weeks 1.8 3.6 15 Normal LSCS 2.8 39
304 Padma 27 69982 Primi No 9 weeks 1.3 6.6 16 Normal LSCS 3 40
305 Sivakalai 22 67854 Primi No 6 weeks 0.7 3.9 12.3 Normal LSCS 2.8 39
306 Nirmala 33 54673 G2A1 No 9 weeks 1.4 3.5 13.6 Normal LSCS 3.5 40
307 Mala 25 67589 G2P1L1 No 6 weeks 1.5 3.5 14.6 Normal LSCS 3.3 40
308 Vanidevi 30 67854 Primi No 8 weeks 1.3 4.2 15.6 Normal LSCS 3.1 40
309 Vanitha 28 65789 G2A1 No 11 weeks 1.5 5.7 13.5 Normal LN 2.7 39
310 Vanisree 23 65478 G2A1 No 7 weeks 0.9 3.2 12.5 Normal LN 3.5 39
311 Janitha 24 67578 Primi No 9 weeks 1.3 4.6 13.6 Normal Forceps 2.8 40
312 Thendral 32 45632 G2A1 No 6 weeks 1.6 5.1 15.6 Normal LN 3.1 39
313 Raji 30 87657 Primi No 8 weeks 1.2 4.2 16.7 Normal LN 3.2 40
314 Duri 24 87965 G2A1 No 10 weeks 1 4.3 13.2 Normal LSCS 3.5 40
315 Deepika 30 67896 G3P2L0 No 9 weeks 1.4 5.4 12.5 Normal LSCS 3.5 40
316 Thoorika 26 67854 Primi No 11 weeks 1.8 5.4 13.7 Normal LSCS 2.9 39
317 Rampriya 25 67543 Primi No 8 weeks 0.7 6.3 12.4 Normal LSCS 3.5 39
318 Kavitha 30 87654 G2A1 No 11 weeks 1.5 5.5 12 Normal LSCS 3.5 36 Preterm
319 Lavina 31 54673 Primi No 9 weeks 1 3.1 13.1 Normal LSCS 3.5 40
320 Lakshmi 25 67854 G2A1 No 6 weeks 1.7 4.4 13 Normal LN 3.1 39
321 Durga 24 65789 Primi No 10 weeks 2 3.9 14 Normal LN 3.5 40
322 Deepa 29 65478 G2P1L1 No 9 weeks 1.7 5.3 14.5 Normal LN 2.9 39
323 Shakthi 30 65789 Primi No 7 weeks 1.8 4 12.7 Normal Forceps 2.9 40
324 Krishna 25 89076 G3P2L0 No 8 weeks 1.5 3.5 12.6 Normal LN 3.1 40
325 Bhavna 31 45632 Primi No 11 weeks 1.2 3.1 12.5 Normal LN 2.6 40
326 Pramodhi 24 89061 Primi No 10 weeks 1.5 4.4 15.6 Normal LN 3.5 39
327 Gowri 26 77891 G2A1 No 9 weeks 0.9 3.9 15 Normal LSCS 2.6 39
328 Vaishali 30 77890 Primi No 7 weeks 0.7 5.3 14 Normal LSCS 2.9 40
329 Tejasree 17 87996 G2A1 No 8 weeks 1.5 4 12 Normal LSCS 3.1 39 Gdm
330 Srinidhi 31 65743 G2A1 No 6 weeks 1.4 3.5 14 Normal LSCS 3 40
331 Subha 24 87997 G2P1L1 No 9 weeks 0.8 6.5 15 Normal LSCS 2.6 40
332 Minu 30 77876 Primi No 10 weeks 1.8 6.4 15 Normal LSCS 3.1 40
333 Dheera 18 77689 G2A1 No 8 weeks 1.4 5.8 16 Normal LSCS 3.3 39
334 Saipriya 23 89062 Primi No 11 weeks 1.8 4.6 14.4 Normal LSCS 2.9 39
335 Kavitha 28 77865 G2A1 No 9 weeks 2 4.9 13.6 Normal LSCS 3 36
336 Soundarya 22 87907 Primi No 7 weeks 1.5 5.7 12.5 Normal LSCS 3.1 40
337 Nandhini 30 87965 G2A1 No 8 weeks 1 5.6 14.5 Normal LSCS 2.6 40
338 Janani 19 89064 Primi No 11 weeks 2 3.5 12.5 Normal LSCS 2.8 39
339 Sangini 24 87977 G2P1L1 No 9 weeks 0.7 5.7 13.6 Normal LSCS 2.9 40
340 Dhina 30 87995 Primi No 10 weeks 1.2 5.4 14.6 Normal LSCS 3 39 Gdm
341 Jasdeep 28 87996 Primi No 11 weeks 0.8 6.2 15.6 Normal LSCS 3.1 40
342 Manjula 19 87905 G2A1 No 9 weeks 1.8 4.6 13.5 Normal LSCS 2.7 40
343 Meena 24 87996 No 10 weeks 1 3.1 12.5 Normal LSCS 3.5 40
344 Kalpana 18 98076 Primi No 8 weeks 1.5 5.7 13.6 Normal LSCS 2.8 39
345 Sonia 24 89076 Primi No 7 weeks 2 5.5 15.6 Normal LN 3.1 39
346 Kavya 30 99887 G2A1 No 9 weeks 1.5 5.6 16.7 Normal LN 3.2 40
347 Darshini 33 69876 Primi No 10 weeks 1.4 3.5 13.2 Normal LN 3.5 39
348 Meera 28 99888 Primi No 8 weeks 1.7 4.2 12.5 Normal Forceps 3.5 40
349 Fahima 24 77896 Primi No 11 weeks 1.5 4.1 13.7 Normal LN 2.9 40
350 Mary 19 89076 G2A1 No 9 weeks 1.8 4.6 15.6 Normal LN 3.5 40
351 Catherine 30 88976 Primi No 6 weeks 1.7 5 13.7 Normal LSCS 3.5 39
352 Asha 28 87906 Primi No 8 weeks 0.7 4.9 14.8 Normal LSCS 3.5 39
353 Priyanka 32 54688 G2A1 No 7 weeks 1 5.4 15 Normal LSCS 3.1 36
354 Dhanam 25 97654 G2A1 No 9 weeks 0.9 6.7 16 Normal LSCS 3.5 40
355 Varsha 24 70986 Primi No 6 weeks 2 4.2 12.3 Normal LSCS 2.9 36
356 Sangeetha 30 78965 Primi No 8 weeks 1.2 5.7 13.6 Normal LSCS 2.9 40
357 Niranjana 28 67889 G2A1 No 9 weeks 2.3 5.5 14.6 Normal LSCS 3.1 39
358 Madhumitha 24 78960 Primi No 10 weeks 1.4 3.5 15.6 Normal LSCS 2.6 40
359 Vahitha 30 56778 Primi No 8 weeks 1.5 5.4 13.5 Normal LSCS 3.5 39
360 Subadra 23 78961 G2A1 No 7 weeks 2.2 5.7 10.3 Normal LSCS 2.6 40
361 Vaishnavi 18 56744 Primi No 9 weeks 1.8 5.6 10.5 Normal LSCS 2.9 39
362 Parimala 30 78962 Primi No 6 weeks 2.4 5.6 12.4 Normal LSCS 3.1 40
363 Manju 29 78963 G2A1 No 8 weeks 2 5.7 12 Normal LN 3 40
364 Kalpana 30 78964 Primi No 10 weeks 1.2 5.7 13.1 Normal LN 2.6 40
365 Shakthi 31 87654 Primi No 9 weeks 2.4 3.5 13 Normal LN 3.1 39
366 Dheera 29 78964 G2A1 No 11 weeks 1 4.4 14 Normal Forceps 3.3 36 Preterm
367 Thangam 28 56744 Primi No 8 weeks 2 3.9 14.5 Normal LN 2.9 40
368 Srividhya 29 78964 Primi No 6 weeks 1 5.3 12.7 Normal LN 3 39
369 Ramya 17 78654 G2A1 No 9 weeks 1.5 4 12.6 Normal LN 3.1 39
370 Kavya 30 56778 Primi No 7  weeks 0.7 3.5 12.5 Normal LSCS 2.6 39
371 Sanjana 29 78906 Primi No 10 weeks 1.7 6.5 15.6 Normal LSCS 2.8 40
372 Vennila 18 78908 Primi No 8 weeks 1.8 6.4 15 Normal LSCS 3.5 37
373 Kalyani 28 77890 G2P1L1 No 11 weeks 0.7 5.8 14 Normal LSCS 3.1 36
374 Punitha 29 78665 Primi No 9 weeks 0.6 4.6 12 Normal LSCS 3.5 40
375 Usha 31 65432 Primi No 6 weeks 1.2 5.6 14 Normal LSCS 2.9 39
376 Anitha 23 78994 G2A1 No 8 weeks 1.6 3.1 15 Normal LSCS 2.9 40
377 Ranjitha 24 90876 Primi No 10 weeks 0.9 5.5 15 Normal LSCS 3.1 39
378 Thara 28 98765 G2P1L1 No 9 weeks 1.7 6.3 16 Normal LSCS 2.6 40
379 Sultana 29 98776 Primi No 7 weeks 1.5 6.3 14.4 Normal LSCS 3.5 40
380 Firduoz 25 87960 Primi No 8 weeks 2 5.7 13.6 Normal LN 2.6 40
381 Isha 28 90875 G2P1L1 No 6 weeks 1.8 5.2 12.5 Normal LN 2.9 39
382 Hasini 24 78896 Primi No 9 weeks 1.8 5.5 14.5 Normal LN 3.1 39
383 Vaishali 17 67888 G3P2L0 No 6 weeks 1.2 5.7 13.6 Normal Forceps 3 36 Iugr
384 Vishwa 28 78891 Primi No 10 weeks 0.8 6.7 13.5 Normal LN 2.6 40
385 Sharmila 29 78892 Primi No 9 weeks 1.5 4.2 13.7 Normal LN 3.1 39
386 Sunitha 23 78868 G2A1 No 7 weeks 1.9 5.6 14.8 Normal LN 3.3 39
387 Salma 32 65478 Primi No 8 weeks 2 6.7 15 Normal LN 2.5 39
388 Rishi 28 78890 Primi No 10 weeks 0.7 6.5 16 Normal Forceps 3 40
389 Nishitha 29 78654 Primi No 11 weeks 1.8 5.6 12.3 Normal LN 3.1 37
390 Lakshmi 19 79806 Primi No 9 weeks 1.9 4.7 13.6 Normal LN 2.6 38
391 Kavipriya 29 78906 G2P1L1 No 10 weeks 1.2 4.4 14.6 Normal LN 2.8 36 Iugr
392 Mini 28 78901 Primi No 7 weeks 1.9 3.9 15.6 Normal LSCS 2.6 40
393 Deepika 26 78902 G2P1L1 No 9 weeks 1.4 5.3 13.5 Normal LSCS 3.5 39
394 Meena 24 78965 Primi No 10 weeks 2 4 12.5 Normal LSCS 2.6 40
395 Rathika 24 78904 Primi No 8 weeks 0.7 3.5 13.6 Normal LSCS 2.9 39
396 Keerthana 27 87967 G2P1L1 No 11 weeks 1.8 6.5 15.6 Normal LSCS 3.1 40
397 Monica 23 78905 Primi No 9 weeks 1.5 6.4 16.7 Normal Forceps 3 40
398 Iswarya 24 89076 Primi No 10 weeks 0.9 5.8 13.2 Normal LN 2.6 40
399 Priyanka 18 78669 G2P1L1 No 7 weeks 1.4 4.6 12.5 Normal LN 3.1 39
400 Vaishali 25 78995 Primi No 9 weeks 1.2 4.5 13.7 Normal LN 3.3 38
